

# MASSACHUSETTS LIFE SCIENCES CENTER



## Fiscal Year 2015 Annual Report



# MASSACHUSETTS LIFE SCIENCES CENTER



**To:** Governor Charlie Baker  
Secretary of Administration and Finance Kristen Lepore  
Secretary of Housing & Economic Development Jay Ash  
Senate President Stan Rosenberg  
Speaker of the House Robert DeLeo  
State Comptroller Thomas G. Shack III  
Clerk of the Senate William Welch  
Clerk of the House of Representatives Steven James

**By forward:** House and Senate Committees on Ways and Means and the Joint Committee on Economic Development and Emerging Technologies

**Date:** September 30, 2015

**Re:** FY 2015 Annual Report of the Massachusetts Life Sciences Center


The Massachusetts Life Sciences Center (MLSC) respectfully submits this Annual Report detailing the organization's operations and accomplishments during Fiscal Year (FY) 2015.

For the past seven years, the MLSC has led the state's life sciences initiative – a \$1 billion initiative designed to strengthen the state's economy by accelerating the growth of our life sciences sectors in Massachusetts. The MLSC's goal has been to make Massachusetts the strongest life sciences ecosystem in the world and the best place in the world for life sciences companies to do business.

The MLSC collaborates with the private sector to accelerate the pace of innovation and economic development in all regions of Massachusetts. The MLSC's strategy has been based on the belief that the best role for the state is to invest in Massachusetts' innovation capacity – the ability to produce and commercialize a flow of innovative life sciences technologies over the long term. Since 2008, the MLSC has invested aggressively in five "enablers" that build innovation capacity: translational research, entrepreneurship, workforce development, infrastructure and collaboration.

This report and the accompanying FY 2015 Audit Report are submitted in fulfillment of the requirements mandated by the General Court pursuant to the MLSC's enabling statute of the Massachusetts General Laws, Chapter 23I (formerly Section 7, now Section 15), as amended by Chapter 130 of the Acts of 2008. Financial statements are contained in the accompanying FY 2015 Audit Report by McGladrey LLP.

As always, we appreciate your continued interest and support.



Mike Kennealy, Acting President & Chief Executive Officer

# Table of Contents

<i>The Life Sciences Stampede to Massachusetts</i> .....	1
<i>The Bottom Line</i> .....	2
<i>Massachusetts Company Attraction and Expansion</i> .....	4
<i>Propelling Companies of the Future</i> .....	6
<i>Accelerating the Growth of Early-Stage Companies</i> .....	6
<i>Boosting Early-Stage Milestone Completion</i> .....	8
<i>Investing in Infrastructure</i> .....	9
<i>Infrastructure Investments to Accelerate Innovation</i> .....	9
<i>Training the Next Generation of Life Sciences Talent</i> .....	10
<i>Working Space for Early-Stage Companies</i> .....	11
<i>From Bench to Bedside: Academic Research Matching Grant Programs</i> .....	13
<i>Cooperative Research Matching Grants</i> .....	13
<i>The Massachusetts Neuroscience Consortium</i> .....	13
<i>Training the Next Generation of Life Sciences Experts</i> .....	15
<i>STEM Equipment and Supplies Grant Program</i> .....	15
<i>The Internship Challenge</i> .....	17
<i>Supporting STEM Education and an Inclusive Workforce</i> .....	19
<i>Industry and Job Creation</i> .....	21
<i>The Life Sciences Tax Incentive Program</i> .....	21
<i>Building Partnerships</i> .....	23
<i>International Collaborative Industry Program (ICIP)</i> .....	23
<i>The Universal Partnerships Program (UP)</i> .....	24
<i>The International Partnership Assistant Portal (IP-ap)</i> .....	24
<i>A New Horizon: Galactic Partnerships</i> .....	25
<i>Education and Outreach Partnerships</i> .....	26
<i>Massachusetts Clinical Innovation Gateway</i> .....	26
<i>Participation in Global Conferences and Trade Shows</i> .....	27
<i>BIO International Convention 2015</i> .....	27
<i>Staying Connected</i> .....	28
<i>The Way Forward</i> .....	29
<i>Appendix A: The Board of Directors of the Massachusetts Life Sciences Center as of June 30, 2015</i>	30
<i>Appendix B: Massachusetts Life Sciences Center Scientific Advisory Board as of June 30, 2015</i>	31
<i>Appendix C: 2014-2015 Internship Challenge Host Companies</i>	32
<i>Appendix D: List of Active Certified Life Sciences Companies as of June 30, 2015</i>	35

# The Life Sciences Stampede to Massachusetts

In November 2014, Shire Pharmaceuticals announced the company's plans to move its U.S. life sciences headquarters and 500 additional employees to Massachusetts. The Boston Business Journal published an article on the announcement with the headline "Shire joins biotech stampede into Massachusetts; new HQ and 500 employees coming to Lexington," following a series of announcements by top international biopharma companies, such as Baxter spin-off Baxalta and GE Healthcare, of plans to expand in the Bay State. Fifteen of the top twenty global leaders in biopharma now have a presence in Massachusetts, and many, like Pfizer, Biogen, Novartis, Shire and Sanofi-Genzyme each have over 1,000 employees in the state. Many of these companies had little to no presence here seven years ago. Over the past year we have embraced and incorporated the term, "life sciences stampede" into our message to the world, and we have continued to attract companies large and small from across the globe, bringing thousands of jobs and important new healthcare technologies with them.

In order to build the world's leading ecosystem for life sciences innovation and growth, the MLSC has invested or committed more than \$595 million as of the end of FY 2015 across the state, literally from Cape Cod to the Berkshires. We have leveraged those public dollars with more than \$2 billion of matching outside investment.

Over the past year, we have implemented new strategies, programs and partnerships in an effort to accelerate the commercialization of promising treatments, therapies, and cures that hold great potential for creating jobs, and for improving human health and patient care. This year, we announced the first round of grants under our new Milestone Achievement Program (MAP), a program that provides grant funding to promising early-stage companies to help them perform and complete essential value-creating milestones. At the 2015 BIO International Convention, the MLSC, the Conference of Boston Teaching Hospitals and the University of Massachusetts Memorial Medical Center announced the launch of the Massachusetts Clinical Innovation Gateway, a new web portal that will allow life sciences companies from Massachusetts and around the world to seek opportunities to partner with Massachusetts academic medical centers on research and clinical initiatives. We also took our spirit of collaboration to new horizons, through a collaboration with the Center for the Advancement of Science in Space (CASIS). During FY 2015, in partnership with CASIS, we launched the Galactic Grant Competition, which allowed Massachusetts life sciences companies to compete for up to \$500,000 in grant funding to support experiments on the International Space Station's (ISS) U.S. National Laboratory, and the International Space Station STEM Challenge, a \$50,000 grant competition that allowed Massachusetts middle schools to compete for resources to send a life sciences research experiment to the ISS. In December 2014, the MLSC awarded the first round of grants through our Universal Partnerships (UP) Program, building on our efforts to support and foster international research collaborations with Massachusetts companies.

While continuing to innovate through new programs and initiatives, the MLSC has also continued to run a broad portfolio of programs that have proven successful over past years, including the Accelerator Loan Program, the competitive Capital Program, the Cooperative Research Matching Grant Program, the Internship Challenge and the Tax Incentive Program. These programs continue to fill gaps in the process of innovation, create jobs and support scientific research that holds potential to improve the human condition.




# The Bottom Line

The MLSC’s investment strategy remains focused on public-private collaboration and achieving high leverage on public tax dollars. Since 2008, the MLSC has directly invested or committed more than \$595 million and leveraged more than \$2 billion in third-party investment. In other words, every \$1 of taxpayer money that the MLSC has invested has attracted more than \$3.3 in additional, outside investment. This has created a portfolio of approximately \$2.6 billion in public-private investments in the state’s life sciences ecosystem that would not have existed without the Life Sciences Initiative.

While investing in any industry is not without risk, the MLSC has continued its run of success at making sound investments within the life sciences sectors thanks to the guidance of an experienced and diverse group of leaders and experts that volunteer their time to review applications and conduct a thorough and transparent review process. The multi-disciplinary scientific, investment, business and legal expertise that informs the MLSC’s decisions continues to provide the Center with the knowledge that is needed to determine the best use of public dollars in order to highly leverage the Commonwealth’s funds and deliver major impact.

## MLSC Investment and Commitments to Date by Dollar Amount (June 2008 – June 2015)



The MLSC’s investment portfolio continues to grow and reflects the organization’s strategy of filling development gaps faced by companies of all sizes and strengthening the state’s position as the leader in life sciences. The MLSC invests in five key “innovation enablers”:

- Translational research partnerships between industry and academic institutions;
- Entrepreneurship and the pipeline of early stage companies;
- Workforce development;
- Infrastructure; and
- New models of collaboration within the state and internationally.




---

## The MLSC currently manages a portfolio of over 600 individual grants, loans and tax incentives.

---

### The MLSC's Investments and Commitments to Date by Dollar Amount (June 2008 - June 2015)



Highlights of the MLSC's FY 2015 investment commitments include:

- Capital Grants for 16 infrastructure projects totaling approximately \$27 million in investment or commitment, including five grants to community colleges;
- Equipment and Supply Grants to 44 high schools and middle schools across the state totaling nearly \$3.8 million;
- \$1 million towards the development of a unique Ebola diagnostic test;
- \$550,000 awarded to two companies and two middle schools to conduct research on the International Space Station;
- More than \$2.2 million in grants awarded to early-stage companies towards the completion of research and development milestones;
- Tax incentive awards to 11 companies totaling more than \$19 million; and
- Placement of 430 interns at companies across the state.



# Massachusetts Company Attraction and Expansion

The MLSC actively recruits new companies to the state through its marketing efforts and programs highlighting the state's world-class academic institutions, teaching hospitals and research institutes, access to a talented workforce and a vibrant investment community. The MLSC also makes companies, coming to or expanding in Massachusetts, aware of the opportunities to partner with existing industry leaders in all sectors of the life sciences, and to enjoy proximity to innovative young companies, all within a supportive environment for growth.

FY 2015 saw some of the largest life sciences companies in the world announce intentions to launch or expand their presence in Massachusetts, including successful recruitment of such industry giants as Baxter, GE Healthcare and Shire. Alongside MassBio and MassMEDIC, and with sister agencies in state and local government, the MLSC continued to work with companies large and small to attract them to Massachusetts, and to help organize the announcement of expansions, relocations and grand openings. A selection of these announcements is below:

- **Eli Lilly and Company** announced plans to establish a new drug delivery and device innovation center in Cambridge that will help attract top scientists and bioengineers, as well as enhance Lilly's local business development presence. The 23,000 square foot center will open by the end of the year with a planned staff of at least 30 scientists and engineers.
- **Baxter International Inc.** formed a new global innovation and R&D center in Cambridge for Baxter's biopharmaceuticals business, which became a separate, independent global company known as Baxalta as of May 2015. The new facility, eventually slated to reach 200,000 square feet, began operations at the end of 2014. The company plans to employ over 400 people in this facility.
- **GE Healthcare Life Sciences** announced it will create a new U.S. headquarters in Marlborough. The company will be making a \$21 million investment in the facility which will house more than 500 employees, including the creation of more than 220 new jobs.
- **EMD Serono, Inc.**, an affiliate of Merck KGaA, announced the official site opening of their new Sagamore Building in Billerica, MA. EMD Serono had 854 employees across Massachusetts as of last year and plans to expand by 20%.
- **Shire** announced plans to establish its U.S. operational headquarters in Lexington moving more than 500 staff to the location from its Chesterbrook, Pennsylvania site. Shire said the move will save the company \$25 million annually starting in 2016.
- **Philips** signed a \$25 million, five-year research alliance with MIT and is moving its U.S. R&D headquarters to Cambridge from its current headquarters in Westchester County, New York.
- **Amgen** announced that it would expand its research center in Kendall Square and add more jobs from locations across the country to its 250 employees already in Massachusetts.



EMD Serono

**Baxter**

**Shire**

*Lilly*

**AMGEN**

**PHILIPS**



# Massachusetts Company Attraction and Expansion

- **Tyrogenex**, a leader in the development of novel kinase inhibitors to target angiogenesis opened a new office in Needham.
- **Xcovery**, a developer of next-generation targeted therapeutics for cancer, announced the opening of a new office in Needham.
- **SIRION Biotech**, a viral vector platform company known for creating viral vector solutions for industry and academic partners, committed to opening a new office in Massachusetts.
- **MCC Global Laboratories Inc.**, developers of Elephant™, an innovative terminal cleaning solution for the healthcare market, established operations in Beverly.
- **Whale Imaging Inc.**, a leading manufacturer of surgical imaging systems first recruited to the state in 2013, opened a new 9,000 square foot facility in Waltham.
- **CONTINUUS Pharmaceuticals Inc.** announced the official opening of its new 3,800 square foot facility in Woburn. This is the company's first facility since spinning out of the Novartis-MIT Center for Continuous Manufacturing in 2012.
- **WuXi AppTec**, an open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries with operations in China and the United States, celebrated the grand opening of its innovation hub network office in Cambridge.
- **Dicerna Pharmaceuticals, Inc.**, a leader in the development of RNAi therapeutics, opened a new 37,000 square foot office and state-of-the-art R&D laboratory in Cambridge's Alewife neighborhood.
- **Voyager Therapeutics**, a gene therapy company treating diseases of the central nervous system, celebrated the opening of its new headquarters in Cambridge.
- **Nihon Kohden**, based in Japan, opened its first U.S. facility in Cambridge. The facility is approximately 1,600 square feet and the company plans to hire 5 people in the first year.
- **ORYZON Genomics**, announced that the company is opening a U.S. operation which will be located in Cambridge.
- **MediSapiens**, after being incorporated in the U.S. at the end of 2013, fully launched its operations in Massachusetts with offices in the Cambridge Innovation Center.
- **Bio-Pact**, a manufacturer of next-generation carbon nanotubes, announced the relocation of its corporate headquarters from Phoenix, Arizona to Cambridge.



# Propelling Companies of the Future

## Accelerating the Growth of Early-Stage Companies

In FY 2015, the MLSC continued its commitment to entrepreneurship and the pipeline of new life sciences companies in Massachusetts by awarding nearly \$5 million in Accelerator Loans to five early-stage companies. To date, Accelerator companies have raised more than \$200 million in funding and acquisition proceeds subsequent to receiving a loan from the MLSC.

The MLSC's Accelerator Loan Program provides working capital to early-stage life sciences companies at a critical stage in their development. This program seeks to de-risk these companies for future – usually private – investment by funding the steps necessary to achieve critical milestones. Some of these companies may hold the promise of becoming the next Philips or Genzyme, while others will be acquired by large companies that are increasingly depending on “external innovation” for growth. Creative entrepreneurs developing promising technologies fuel Massachusetts’ vibrant innovation culture which has been a fundamental factor in attracting larger companies to set up operations in Massachusetts. Likewise it continues to draw global life science leaders to expand in Massachusetts, in order to have a front-row seat to the breakthroughs that are happening here.

During FY 2015, the MLSC administered two rounds of the Accelerator Loan Program, receiving a total of 46 applications, of which 42 were eligible for review by experts selected from among the MLSC’s 200-plus volunteer peer reviewers. The MLSC’s peer reviewers recommended 31 of these applicants for review by the MLSC’s Scientific Advisory Board (see Appendix B). Eleven companies were then recommended by the Scientific Advisory Board (“SAB”) for due diligence and review by the Investment Subcommittee of the MLSC’s Board of Directors (see Appendix A). Five of these companies were approved for a loan by the full Board of Directors as indicated below:

### Accelerator Loans awarded in FY 2015

Company	Location	Area of Development	Loan Amount
3Derm Systems, Inc.	Cambridge	Designs and deploys a skin imaging system that allows primary care physicians to take clinical-quality 3D images of concerning skin lesions and upload them for instant review by a dermatologist.	\$1,000,000
Parsagen Diagnostics, Inc.	Boston	Develops rapid non-invasive diagnostic tests with unprecedented accuracy in predicting preterm birth within 7 and 14 days of presentation.	\$1,000,000
Sabik Medical, Inc.*	Sudbury	Develops radiopharmaceuticals to image and treat serious cancers.	\$1,000,000
Windgap Medical, Inc.	Somerville	Developing a compact and easy to use epinephrine autoinjector for the treatment of anaphylaxis.	\$999,696
X4 Pharmaceuticals, Inc.**	Belmont	Develops oral small molecule CXCR4 antagonist therapeutics for the treatment of several different cancers.	\$1,000,000

\*Sabik Medical's award was based on achieving certain closing conditions which were not achieved. Consequently the award was terminated in the spring of 2015.

\*\*Subsequent to June 30, 2015, X4 Pharmaceuticals informed the MLSC that it had raised \$37 million in private financing and therefore the company became ineligible for the loan award.



## *This fiscal year saw a number of Accelerator portfolio companies receive regulatory approvals and additional outside investment*



In FY 2015, Cristcot Inc., an awardee from FY 2012 based in Concord, raised over \$3 million in equity. They also announced that they secured a supply partnership with a large healthcare provider group purchasing organization. Last year, Cristcot launched their breakthrough product, Sephure.



Bio2 Technologies, Inc., an FY 2013 awardee, received important 510k clearance from the U.S. Food and Drug Administration ("FDA") for its CLM Bioactive Scaffold. The Woburn-based company is also working on a suite of products for use in reconstructive surgery of the extremities.



Arch Therapeutics, Inc., a Framingham-based medical device company and FY 2013 awardee, announced that it raised \$5 million in equity and debt financings. The proceeds of this fundraising will help the company continue to develop their technology and commercialize their device to achieve hemostasis in minimally invasive and open surgical procedures.



Myomo, Inc., a Cambridge-based Accelerator awardee from FY 2012, raised nearly \$5 million in a Series B-1 financing. This additional funding will allow the medical device company, which specializes in myoelectric orthotics, to support investments in sales and marketing, new product development, and expanded clinical trials.



An FY 2011 awardee, Allurion Technologies (formerly-known-as SGL Medical) from Wellesley raised more than \$3 million. This awardee has developed a medical device to treat obesity, the Elipse™, that does not require surgery, endoscopy or anesthesia.

---

**From the Accelerator Loan Program's inception through the end of FY 2015, the MLSC has funded or committed to lend a total of approximately \$22.7 million in Accelerator Loans to 32 early-stage companies.\***

---

\*Three companies that have received Accelerator Loans in the past have ceased operations, including Grove Instruments, Inc., an FY 2011 loan recipient, which ceased operations in the spring of 2015.



# Boosting Early-Stage Milestone Completion

In FY 2015, the MLSC launched a new grant program aimed at early-stage life sciences companies that need to complete a critical milestone in order to attract additional outside funding and propel the future development of their technology. After an analysis of the current funding environment, and in-depth discussions with early-stage life sciences entrepreneurs, investors, and mentors, the MLSC discovered an existing gap and structured the Life Sciences Milestone Achievement Program (MAP) to help fill that need.

The MAP launched in November 2014 and applications were due on February 2, 2015. The inaugural round of the MAP attracted 98 applications, of which 52 were eligible for review by experts selected from the MLSC's peer review panel and SAB. An SAB member chaired the program and oversaw the review process. The MLSC's review panel recommended 24 of these applicants to move forward in the process, where applicants addressed reviewers' questions. The applicant responses and applications were discussed in a review meeting, where 16 finalists were recommended to advance to the Investment Committee of the MLSC's Board of Directors. Twelve of these companies were approved for more than \$2 million in grants by the Board of Directors as indicated below, enabling these companies to each start work on fundamental milestone projects. These milestones involved product development and scale-up, business strategy, clinical and regulatory processes, or market validation and analyses.

Just over 60% of MAP awardees had proposed product development milestones; some examples include the development and scale-up of a device to be used for human pre-clinical studies and a first-in-pig demonstration of a working prototype. The remaining awardees had marketing, business, or clinical and regulatory milestones including new patent applications, relocation of manufacturing processes in order to gain regulatory approvals, and clinical effectiveness studies.

The breadth of indications and medical conditions to be addressed by MAP awardees is wide; therapeutics and diagnostics for diseases such as cancer, cardiovascular disease, and ALS are being developed, as well as various solutions for insomnia, chronic pain, and wound healing.

## MAP Grants awarded in FY 2015

Company	Location	Milestone	Grant Amount
Akita Innovations, Inc.	North Billerica	Product Development	\$168,955
Aquinnah Pharmaceuticals, Inc.	Cambridge	Product Development	\$200,000
Cognition Medical Corp.	Cambridge	Product Development	\$190,000
Cre8MDI LLC	Chelmsford	Product Development	\$200,000
Energesis Pharmaceuticals Inc.	Cambridge	Product Development	\$200,000
Extend BioSciences Inc.	Cambridge	Business Milestone	\$200,000
InsomniSolv, Inc.	Beverly	Clinical / Regulatory	\$83,380
LayerBio, Inc.	Arlington	Manufacturing Scale-Up	\$200,000
MCC Global Laboratories, Inc.	Beverly	Clinical / Regulatory	\$200,000
Micro-Leads, Inc.	Boston	Product Development	\$200,000
PathMaker Neurosystems Inc.	Boston	Product Development	\$200,000
Platelet Biogenesis, Inc.	Chestnut Hill	Product Development	\$200,000



# Investing in Infrastructure

The MLSC's investments in infrastructure are funded through the MLSC's Capital Fund, which expended over \$77.6 million in FY 2015 as part of the state's overall capital plan. Through the Life Sciences Initiative, half of the resources committed (\$500 million of the total \$1 billion) are dedicated to capital projects.

The MLSC is committed to using its capital fund to ensure that the resources and infrastructure needed to maintain and strengthen our position as the global life sciences leader are in place across the entire Commonwealth. In support of this commitment, the MLSC uses its grants to engage and build on the strengths of the state's different regions and to ensure that institutions and regions across the state have the necessary infrastructure to contribute in meaningful ways to the fastest growing industry in the state.

To date, the MLSC's infrastructure investments have contributed or will contribute to the creation of more than 1.5 million square feet of new life sciences research and manufacturing space across the Commonwealth, while creating more than 4,300 jobs in the building trades and in the life sciences.

In response to our FY 2015 (fourth annual) competitive solicitation, the MLSC received 51 eligible applications for infrastructure projects from across the state. The MLSC's Board of Directors approved 10 new Capital Project Grants, five Equipment and Supply Grants for community colleges and a planning grant. These investments are summarized below:

## Infrastructure Investments to Accelerate Innovation

### **Boston University/Boston Medical Center (Boston)**

Boston University and Boston Medical Center were awarded over \$1.7 million to launch an expansive Lung Regeneration Initiative (LRI) as part of their Center for Regenerative Medicine. The goal of the LRI is the clinical application of recent BU-led discoveries in stem cell research, such as the treatment of lung diseases with personalized therapeutics, as well as the ultimate reconstitution of diseased lung epithelia in patients with emphysema. The LRI also aims to define and launch treatments for pulmonary fibrosis, pulmonary hypertension, cystic fibrosis, and acute lung injury from inhaled pathogens.

### **Boston Children's Hospital (Boston)**

Boston Children's Hospital was awarded over \$2.2 million to enable an existing human neuron differentiation service to merge with an existing cellular assay development and screening core in a newly renovated core facility called the Human Neuron Core. The creation of this new resource at BCH will accelerate research into new treatments that will specifically benefit children with neurodevelopmental, psychiatric and neurological disorders to broadly facilitate new avenues of research for clinical investigators who lack direct experience in stem cell biology.

### **Brigham and Women's/Forsyth Institute (Boston/Cambridge)**

The Forsyth Institute and Brigham & Women's Hospital were awarded over \$4.8 million to fund the creation of the Massachusetts Host-Microbiome Center, which will accelerate practical understanding of how personal microbial communities interact to promote health or cause disease. The project draws upon unique expertise among state institutions that have pioneered functional systems to identify causative effects of microbial communities in vivo, namely The Forsyth Institute, Brigham & Women's Hospital, Boston Children's Hospital and the Harvard Digestive Diseases Center.

### **Massachusetts Institute of Technology (MIT) (Cambridge)**

MIT received over \$1.8 million for a project aimed at establishing new genetic models for brain disorders research. The project will take advantage of the recently developed CRISPR technology, a powerful method for making precise genetic changes in living cells and organisms. The focus of the project is on psychiatric disorders, which are among the most disabling yet poorly understood human diseases, but the technology platform will be widely applicable to many questions in basic and translational neuroscience.



### **University of Massachusetts Medical School (Worcester)**

UMass Medical School was awarded \$5 million to support a joint venture with Harvard Medical School to establish a facility for High Resolution Cryo-Electron Microscopy (Cryo-EM). Cryo-EM is a critical new technology for studying the relationships between structure and function in large molecular complexes within cells. One of the most important new tools for drug design and development, Cryo-EM will play a critical role in identifying likely therapeutic approaches for a broad range of diseases, particularly neurological disorders such as Alzheimer's, immunological disorders, and diabetes.

**"Our medical school feels privileged to be part of an initiative that illustrates why Massachusetts is leading the nation in life sciences research, investment and innovation."**

*- Michael F. Collins, Chancellor of UMass Medical School*

## **Training the Next Generation of Life Sciences Talent**

### **Bay Path University (Longmeadow)**

Bay Path University in Longmeadow was awarded \$500,000 to purchase science equipment and supplies that will enable the University to expand opportunities for collaborative student research and through the integration of new science equipment, better prepare young women for career success in the life sciences sectors.

### **Berkshire Community College (Pittsfield)**

Berkshire Community College (BCC) was awarded \$500,000 in funding to launch an educational underpinning that will support the development of the Berkshire Innovation Center (BIC). BCC plans to purchase state-of-the-art reverse engineering equipment and 3-D prototype printers, and develop new courses, which will help to establish a foundation to provide students with advanced learning opportunities.

### **Boston University's Biomedical Laboratory and Clinical Sciences (BLCS) Program (Boston)**

BLCS received \$180,000 in funding to enhance the quality of the training, add to the competencies of the students and to enable the BLCS program to obtain essential equipment. BLCS purchased a small bioreactor, a small bench top fluorescence activated cell analyzer, and implemented an electronic laboratory information and management system to train students for the changing environment for record keeping in the biotech industry.

### **Holyoke Community College (Holyoke)**

Holyoke Community College (HCC) was awarded \$300,000 to purchase biotechnology equipment and supplies. This request is part of a larger capital project, for which HCC received a \$3.8 million award from the MLSC in 2013 for 13,000 square feet of lab space and the creation of a Center for Life Sciences. This includes

a clean room for the biological sciences, which will be the only clean room in Western Massachusetts to support training for students, faculty and industry partners. The construction is expected to be completed during the 2017-2018 school year.

### **Just-A-Start Corporation (Cambridge)**

Just-A-Start Corporation (JAS) was awarded \$49,992 to improve classroom technology and equipment for its Biomedical Career Program (BCP). The BCP provides opportunities for low and moderate income adults to obtain entry level positions and increase their earning potential. The biomedical industry is able to hire from a diverse group of prepared graduates of this free nine-month program. Participants receive academic training in science and technology and laboratory skills and a certification in collaboration with Bunker Hill Community College.

### **Quinsigamond Community College (Worcester)**

Quinsigamond Community College (QCC) was awarded \$5 million to enhance its existing life sciences programming and expand the college's life sciences and biotechnology programming into Southbridge and downtown Worcester. Last fiscal year, QCC received \$499,880 in funding from the MLSC to support and enhance the school's life sciences training facilities located on their main campus in Worcester.

### **Regis College (Weston)**

Regis College was awarded \$355,000 to invest in critically needed equipment that will provide life sciences education opportunities to underserved populations. The grant will also better prepare students for graduate studies, position Regis for advanced biomedical science and regulatory studies education programs, and increase the number of graduates who will be contributing competitively and substantially to Massachusetts' innovation economy.



### Roxbury Community College (Boston)

Roxbury Community College (RCC) was awarded \$3 million in grant funding to build additional science labs and renovate existing lab space for its new Life Sciences Institute (LSI). The renovations will play a significant role in promoting an environment that fosters innovation and undergraduate student research at RCC, which is critical to maintaining students' interest in the life sciences. RCC's student body is predominately made up of students of color and immigrant communities, uniquely positioning the College to fill the need for a diverse, well-trained and local life sciences workforce.

### Springfield Technical Community College (Springfield)

Springfield Technical Community College (STCC) was awarded \$1,000,000 to establish a Biomedical Engineering Technology associate's degree program

with two BMET (Biomedical Instrumentation and Biomedical Device Manufacturing) tracks, and to enhance STCC's existing Biotechnology associate's degree program. As the only technical community college in Massachusetts, STCC has an on-going need for up-to-date industry-aligned equipment and lab space for life sciences programs.

### Wellesley College (Wellesley)

Wellesley College was awarded a \$50,000 grant to support the planning and design phase of the renovation and modernization of their Science Center. The grant will be used to plan for laboratories and teaching facilities that will increase faculty research capabilities, enhance faculty recruitment, and strengthen the learning experience so more students will persist in science majors and go on to STEM careers.

## Working Space for Early-Stage Companies

### Boston University Business Innovation Center (Boston)

The Boston University Innovation Center was awarded \$363,750 to convert current office space to laboratory space dedicated to fulfilling the needs of start-ups in the biophotonic field. The new laboratory will provide facilities and space for up to four companies. The Boston University Photonics Center (BUPC) is a national leader in biophotonic research, a life sciences speciality that uses light to understand cellular behavior and to diagnose and treat diseases.

Below and on the following page is a list of awards made by the MLSC since the inception of the MLSC capital fund and the status of each project.

### Capital Awards from Inception through June 30, 2015

Infrastructure Investments to Accelerate Innovation	Total Award	Year of Award	Status at End of FY 2015
Boston Children's Hospital	\$4,014,031	FY 2013	Completed
Boston Children's Hospital	\$2,263,133	FY 2015	Ongoing
Boston University Medical School	\$1,743,648	FY 2015	Ongoing
Brigham & Women's Hospital	\$2,603,537	FY 2015	Ongoing
Dana Farber Molecular Cancer Imaging Center	\$10,000,000	FY 2012	Ongoing
Harvard Medical School	\$5,000,000	FY 2013	Ongoing
Joslin Translational Center for the Cure of Diabetes	\$5,000,000	FY 2012	Completed
MA Green High Performance Computing Center	\$4,540,000	FY 2013	Ongoing
Marine Biological Laboratory in Woods Hole	\$10,000,000	FY 2009	Completed
Massachusetts Institute of Technology	\$1,838,000	FY 2015	Ongoing
MassBiologics-UMass Medical School	\$5,000,000	FY 2014	Ongoing
The Forsyth Institute	\$4,133,215	FY 2013	Completed
The Forsyth Institute	\$2,210,229	FY 2015	Ongoing
Tufts/Cummings School of Veterinary Medicine, NE Regional Biosafety Lab in Grafton	\$9,500,000	FY 2009	Completed
UMass Amherst Life Sciences Laboratories	\$95,000,000	FY 2013	Ongoing
UMass Boston /Dana Farber Center for Personalized Cancer Therapy	\$2,000,000	FY 2011	Ongoing
UMass Boston /Dana Farber Center for Personalized Cancer Therapy Expansion	\$8,000,000	FY 2014	Ongoing
UMass Dartmouth Advanced Technology Manufacturing Center (ATMC)	\$11,400,000	FY 2012	Completed



UMass Dartmouth/Vector Manufacturing Center	\$20,600,000	FY 2012	Completed
UMass Lowell Emerging Technologies and Innovation Center	\$10,000,000	FY 2012	Completed
UMass Medical School	\$5,000,000	FY 2015	Ongoing
UMass Medical School Albert Sherman Center	\$90,000,000	FY 2010	Completed

Training the Next Generation of Life Sciences Talent	Total Award	Year of Award	Status at End of FY 2015
Bay Path College	\$50,000	FY 2013	Completed
Bay Path University	\$500,000	FY 2015	Ongoing
Berkshire Community College	\$500,000	FY 2015	Ongoing
Boston University Biomedical Lab and Clinical Sciences Program	\$180,000	FY 2015	Ongoing
Bunker Hill Community College	\$200,000	FY 2013	Completed
Cape Cod Community College	\$395,485	FY 2014	Ongoing
City of Taunton	\$55,000	FY 2014	Ongoing
Framingham State University	\$3,000,000	FY 2014	Ongoing
Holyoke Community College	\$3,800,000	FY 2013	Ongoing
Holyoke Community College	\$300,000	FY 2015	Ongoing
Just-A-Start	\$46,099	FY 2014	Completed
Just-A-Start	\$49,992	FY 2015	Ongoing
MassBay Community College	\$50,000	FY 2014	Ongoing
Middlesex Community College	\$36,664	FY 2013	Completed
Middlesex Community College	\$3,000,000	FY 2014	Ongoing
Mount Wachusett Community College	\$500,000	FY 2014	Ongoing
Museum of Science "Hall of Human Life"	\$5,000,000	FY 2012	Completed
North Shore Biotech Consortium	\$5,000,000	FY 2014	Ongoing
Northern Essex Community College	\$1,242,000	FY 2013	Ongoing
Quincy College	\$94,087	FY 2013	Completed
Quincy College	\$500,000	FY 2014	Ongoing
Quinsigamond Community College	\$310,000	FY 2013	Completed
Quinsigamond Community College	\$499,880	FY 2014	Completed
Quinsigamond Community College	\$5,000,000	FY 2015	Ongoing
Regis College	\$50,000	FY 2013	Completed
Regis College	\$355,000	FY 2015	Ongoing
Roxbury Community College	\$3,000,000	FY 2015	Ongoing
Springfield Technical Community College	\$85,673	FY 2013	Completed
Springfield Technical Community College	\$1,000,000	FY 2015	Ongoing
Wellesley College	\$50,000	FY 2015	Ongoing
Western New England University	\$500,000	FY 2014	Completed
Worcester Polytechnic Institute (Biomanufacturing Education & Training Center)	\$2,950,000	FY 2010	Completed

Working Space for Early-Stage Companies	Total Award	Year of Award	Status at End of FY 2015
BayState Medical Center/Health Informatics & Technology Innovation Center	\$5,500,000	FY 2013	Ongoing
Boston University Business Innovation Center	\$363,750	FY 2015	Ongoing
Gateway Park-MBI	\$2,200,000	FY 2010	Completed
LabCentral	\$4,955,515	FY 2013	Completed
LabCentral	\$5,000,000	FY 2014	Ongoing
New Bedford Economic Development Council	\$75,000	FY 2014	Completed
Pittsfield Economic Development Authority	\$55,000	FY 2013	Completed
Pittsfield Economic Development Authority	\$9,670,000	FY 2014	Ongoing
UMass Boston VDC	\$588,848	FY 2014	Ongoing
UMass Lowell Innovation Hub	\$1,000,000	FY 2014	Ongoing
UMass Lowell M2D2	\$4,046,697	FY 2014	Ongoing
Venture Café	\$347,000	FY 2014	Ongoing

Municipal Infrastructure to Support Life Sciences Growth	Total Award	Year of Award	Status at End of FY 2015
Framingham Wastewater and Pumping Station	\$12,860,534	FY 2009	Completed



# *From Bench to Bedside: Academic Research Grant Programs*

The MLSC's key priorities include preserving the strong competitive position of Massachusetts' academic institutions and medical centers, supporting translational research in the life sciences, and accelerating the discovery and transfer of technology out of academic settings.

## *Cooperative Research Matching Grants*

The MLSC's Cooperative Research Matching Grants encourage industry-sponsored research collaborations with Massachusetts academic institutions to accelerate translational research. Non-profit academic/research institutions and industry partners are eligible to apply for grant funding of up to \$500,000 over two years, provided that the industry sponsor matches the MLSC funds on at least a 1:1 basis. Funds to support these cooperative research projects are given as grants to the academic partner. Since 2008, the MLSC has awarded 18 grants under this program, totaling over \$8.7 million.

In the FY 2015 round of awards, projects were funded to address epilepsy, sepsis, microbial resistance to antibiotics, treatment of severe abdominal hemorrhage, cystic fibrosis and Amyotrophic Lateral Sclerosis (ALS). Research institutions that received awards included Boston Children's Hospital, Fraunhofer Center for Manufacturing Innovation, Harvard University School of Engineering, and Massachusetts General Hospital.

One of these research grants, awarded to Harvard University's School of Engineering, developed a completely new class of instrumentation using microfluidics that can be used in biotechnology and basic medical research, and ultimately for diagnostic purposes. Dr. David Weitz, the Principal Investigator for this grant, explained that: "A new spinoff company was created to exploit this technology. The company is GnuBio which is located in Kendall Square and currently employs over 45 people. These are new biotech jobs in Massachusetts that exist in large part because of the support of the MLSC."

## *The Massachusetts Neuroscience Consortium*

The Massachusetts Neuroscience Consortium was launched in June 2012 at the BIO International Convention in Boston. Charter Consortium members were AbbVie, Biogen, EMD Serono, Janssen, Merck, Pfizer, and Sunovion Pharmaceuticals, Inc. The MLSC used its convening power to bring these companies together to form a new model for collaboration with the research community in order to accelerate the pace of discovery. The Consortium is funded 100% by Consortium members. The MLSC acts as a trustee for the funds and awards are not funded by the MLSC.

For the first solicitation, Consortium members received and evaluated nearly 100 applications, selecting seven pre-clinical projects to fund at Massachusetts academic and research institutions. Selected projects focus on Alzheimer's disease, Multiple Sclerosis, neuropathic pain and Parkinson's disease. Members of the Consortium are working collaboratively with the project Principal Investigators and making good progress.

In December 2014, the MLSC awarded the second round of awards made by the Neuroscience Consortium. Nearly 60 applications were received and Consortium members selected six pre-clinical projects to fund at Massachusetts academic and research institutions with a focus on Multiple Sclerosis, Alzheimer's disease, Amyotrophic Lateral Sclerosis (ALS) and Parkinson's disease. Participating members each committed \$250,000 to the Consortium for this round, for a total of \$1.5 million.

In December 2014, the 13 awardees from both rounds gathered at Merck Research Laboratories in Boston to share their knowledge and progress on projects funded in the first round and to present project aims for projects funded in the second round.



## FY 2015 Cooperative Research Matching Grants

Recipient	Location	Project Description	Grant Amount
Dr. David King / Massachusetts General Hospital in partnership with Arsenal Medical	Boston	Work on the development of a self-expanding foam, ResQFoam, to treat severe abdominal hemorrhage. A key commercialization activity to move this promising technology from bench to point-of-injury is the development of a robust, hand-operated, portable delivery system for foam administration. Arsenal Medical intends to use safety and effectiveness findings from this grant as the basis for product development and regulatory submission of the foam for pelvic bleeding.	\$225,000
Dr. Samuel Moskowitz / Massachusetts General Hospital in partnership with EnBiotix	Boston	Identify the optimal metabolite-tobramycin ratio and dosing of EBX-001 for the treatment of P. aeruginosa infections in cystic fibrosis patients. The regulatory route for EBX-001 is anticipated to be straight-forward given the "generally recognized-as-safe" classification of the metabolite and the great deal of safety and efficacy data that is available for tobramycin. EBX-001 has the potential to significantly reduce the impact of such infections in CF patients by improving mortality and quality of life.	\$191,504
Dr. Alexander Rotenberg / Boston Children's Hospital in partnership with Neuroelectrics	Boston	Conduct a randomized placebo-controlled trial to test whether cathodal transcranial direct current stimulation (tDCS) suppresses seizures in patients with focal seizures. The hypothesis for this research is that repeated daily sessions of cathodal tDCS will lead to a clinically significant decrease in seizures in patients with medically-refractory focal epilepsy. The field of epilepsy research has been turning steadily towards nonpharmacologic options such as focal brain stimulation. Non-invasive neurostimulation techniques, such as tDCS, are uniquely suited to mass distribution and treatment, even at home, as they are lightweight, portable, inexpensive and have a favorable safety profile.	\$448,876
Dr. Alexis Sauer-Budge /Fraunhofer in partnership with AdvanDx	Cambridge	Development of a rapid and low cost system for positively identifying the microbes causing sepsis, which would then lead to faster treatment. Sepsis accounts for 40% of all ICU costs, making it the most expensive condition treated in US hospitals. According to the federal Agency for Healthcare Research and Quality, sepsis cases cost more than \$20 billion to treat in 2011.	\$225,000
Dr. Brian Wainger / Massachusetts General Hospital in partnership with GlaxoSmithKline	Boston	Develop a cell-based personalized medicine platform to optimize selection of clinical trial subjects, create new diagnostics and generate novel medicines to treat diseases such as ALS. Funding from the MLSC will support the in vitro phenotypic analysis of study subject-derived motor neurons, to determine whether such analysis can predict clinical neurophysiological phenotype and the effects of the drug in study subjects.	\$450,000
Dr. David Weitz / Harvard University in partnership with BASF	Cambridge	Develop a microfluidics platform for Droplet-based Microbial Inhibition Testing (Drop-MINT) to enable rapid identification of novel peptides and compounds with anti-microbial properties. If platform development is successful, the technology will be commercialized through a fee-for-service start-up company that will be headquartered in Massachusetts. Harvard's industry partner is BASF, which will have an option to invest in the start-up company via BASF Venture Capital.	\$450,000

## FY 2015 Neuroscience Consortium Awards

Primary Investigator (PI)	Institution	Disease Area	Project Liaison	Project Description	Total Award
Carmela Abraham, Ph.D.	Boston University School of Medicine	Multiple Sclerosis	EMD Serono	Klotho as a novel molecular target for inducing remyelination in MS	\$250,000
Michael Greenberg, Ph.D.	Harvard Medical School	Alzheimer's	Sunovion Pharmaceuticals Inc.	Genome-wide screen for novel negative regulators of synapse number as potential therapeutic targets of Alzheimer's Disease	\$250,000
Bradley T. Hyman, M.D., Ph.D.	Massachusetts General Hospital	Alzheimer's	Janssen Research & Development, LLC	Tau propagation and AD	\$250,000
Tsuneya Ikezu, Ph.D.	Boston University School of Medicine	Alzheimer's	AbbVie	Target validation and development of drug discovery platform for TREM2/TYROBP signaling pathway modulators	\$249,994
Thomas L. Schwarz, Ph.D.	Boston Children's Hospital	Amyotrophic Lateral Sclerosis	Biogen	High-content screen for modulators of mitochondrial otility	\$248,992
Hanno Steen, Ph.D.	Boston Children's Hospital	Parkinson's	Merck	Co-regulation proteomics to identify targets of LRRK2 in Parkinson's	\$250,000



# Training the Next Generation of Life Sciences Experts

## STEM Equipment and Supplies Grant Program

The STEM Equipment and Supplies Grant Program enables the purchase of equipment and supplies for high schools and middle schools in the Commonwealth in order to train students in life sciences technology and research. The program seeks to increase student achievement and student interest in STEM (Science, Technology, Engineering, and Math), as well as support the implementation of state STEM standards.

These grants enable schools to provide a breadth of training ranging from general STEM education curricula to biotechnology and robotics. Our goal is that these grants will help increase the diversity of workers that are being well-prepared for entry-level positions in the life sciences workforce.

Eligible schools include vocational technical high schools, public high schools and middle schools in Massachusetts' Gateway Cities, high schools and middle schools serving a low-income student population, and workforce training programs throughout the state. High schools, and organizations serving such high schools, can apply for up to \$250,000 in grant funding. Applicants seeking funding of greater than \$100,000 (but no more than \$250,000) are required to secure matching funds for any amount over \$100,000 from an industry partner. Middle schools are eligible for up to \$50,000 (no match required).

In December 2014, the MLSC awarded 44 grants across the state totaling nearly \$3.8 million. This includes 30 applicants representing 40 high schools, 14 applicants representing 29 middle schools, and one maker space serving middle school students. Industry sponsors contributed more than \$83,000 in matching funds and in-kind donations as part of this past year's program.



# Schools and Organizations Awarded STEM Equipment and Supplies Grants in FY 2015

School/Organization	City/Town	Award Amount
Attleboro High School	Attleboro	\$68,880
Barnstable High School	Hyannis	\$98,220
Bay Path Regional Vocational Technical High School	Charlton	\$26,510
Blackstone Valley Regional Vocational Technical High School	Upton	\$90,119
Breed Middle School	Lynn	\$50,000
Bristol-Plymouth Regional Technical School	Taunton	\$55,086
Brockton High School	Brockton	\$98,633
Brooke Charter Schools (East Boston; Mattapan; Roslindale)	Boston	\$48,000
Cambridge Rindge and Latin School & Massachusetts Academy of Math and Science	Cambridge/ Worcester	\$100,000
Chicopee Comprehensive High School	Chicopee	\$83,086
Codman Academy Charter School	Dorchester	\$8,830
East Boston High School	East Boston	\$88,230
Everett High School	Everett	\$99,949
Fitchburg High School	Fitchburg	\$99,216
Fitchburg Public Schools (Arthur M. Longsjø, Jr.; Memorial)	Fitchburg	\$99,095
Franklin County Technical School	Turners Falls	\$99,557
Global Learning Charter Public (Middle) School	New Bedford	\$43,698
Joseph P. Keefe Technical School (South Middlesex Technical School District)	Framingham	\$98,820
Lowell High School	Lowell	\$100,000
Lowell Makes	Lowell	\$50,000
Lowell Middlesex Academy Charter School	Lowell	\$90,726
Lynn Vocational Technical Institute	Lynn	\$99,908
Massachusetts Biotechnology Education Foundation (MassBioEd)	Cambridge	\$139,999
Medford Vocational Technical High School	Medford	\$99,979
Minuteman Career and Technical High School	Lexington	\$88,971
New Bedford Public Schools (Roosevelt; Normandin; Keith)	New Bedford	\$50,000
North Brookfield High School	North Brookfield	\$96,750
Old Colony Regional Vocational Technical High School	Rochester	\$93,620
O'Maley Innovation Middle School	Gloucester	\$21,566
Quabbin Regional High School	Barre	\$99,147
Quaboag Regional Middle High School	Warren	\$100,000
Quincy Public (Middle) Schools (Atlantic; Broad Meadows; Central; Point Webster; Sterling)	Quincy	\$49,689
Resiliency Middle School	Fall River	\$48,000
Revere High School	Revere	\$96,306
Revere Public (Middle) Schools (Garfield; Rumney Marsh Academy; Susan B. Anthony)	Revere	\$149,986
South Shore Vocational Technical School District	Hanover	\$133,000
Springfield High School of Commerce	Springfield	\$99,991
Thurgood Marshall Middle School	Lynn	\$50,000
Tri-County Regional Vocational Technical High School	Franklin	\$98,963
Upper Cape Cod Regional Technical School	Bourne	\$99,666
Veritas Preparatory Charter School	Springfield	\$50,000
Waltham High School	Waltham	\$98,742
Worcester Public Schools (Burncoat; Worcester East; Forest Grove; Sullivan; Claremont; UPCS)	Worcester	\$265,142
Zanetti Montessori Magnet School	Springfield	\$48,456




# The Internship Challenge

The year-round Internship Challenge has continued to be the MLSC's flagship workforce development program, creating nearly 1,900 paid internship opportunities at nearly 500 life sciences companies throughout the Commonwealth. Interns have represented 180 different colleges and universities.

The Internship Challenge focuses on enhancing the talent pipeline for life sciences companies while providing students and recent graduates with practical, "hands-on" experience that prepares them to step into the workforce ready to meet the job requirements of life sciences employers. The program subsidizes paid internships for undergraduate sophomores, juniors and seniors; community college students; Master's students; and recent college graduates.

## Intern Host Companies by Region



Western	4%
Central	8%
MetroWest	18%
Northeast	17%
Greater Boston	49%
Southeast	4%

Host companies commit to providing a dedicated mentor and a meaningful internship opportunity related to the academic focus of their interns. The MLSC provides an online interface to connect host companies with student candidates; students complete an online application, which includes a cover letter and their resume, and host companies review applications to match skills with their needs. Host companies can hire up to two interns per year, but have the option to hire an additional two interns that are enrolled in a community college. At the conclusion of the internship, the MLSC reimburses companies for intern stipends of up to \$7,200, which allows for 12 weeks of full-time work at the maximum reimbursable pay rate of \$15 per hour.

The MLSC conducts a survey of both interns and sponsors at the conclusion of each internship period because the MLSC believes that the Internship Challenge participants themselves provide the best evidence of the program's value and impact. Surveys of participating interns show that over 30% of the interns that were entering the workforce (recent graduates) found immediate full-time employment as a result of their internships. In most cases, these interns were hired by the company that hosted their respective internships.

---

**92%** of responding interns indicated that their internship met or exceeded their expectations. **88%** of responding interns indicated that their internship reinforced their interest in working in the life sciences.

---

---


Surveys of participating companies show that **96%** indicated that their intern(s) met or exceeded their expectations. **81%** of companies indicated that the technical skills demonstrated by intern(s) were comparable to their best hires at this stage in their educational and career development.

---



The Internship Challenge is designed to expand the pool of prospective employees who have practical experience, enhance opportunities for mentoring, enable more students to explore career opportunities, provide students interested in working in the life sciences with a peer network through educational and informational exchange events, and expose students to entrepreneurship.


## Distribution of Internship Challenge Companies by Company Sector



The Internship Challenge is also a human-capital subsidy program for small and early-stage companies. The MLSC only reimburses intern stipends for companies with 100 or fewer employees in Massachusetts (and up to 250 globally). Because participating interns work in smaller companies, they also receive exposure to the dynamic entrepreneurial environment.

In FY 2015, more than 2,000 students and recent graduates submitted applications for review by more than 300 companies across Massachusetts. The 2014-2015 program placed a total of 430 interns with 234 host companies (see Appendix C for a complete list of 2014-15 Internship Challenge host companies). Interns were demographically diverse and represented 92 different colleges and universities. The Internship Challenge program is broadly inclusive, as the data in this section illustrates.

## Academic Major of Participating Interns



# Supporting STEM

(Science, Technology, Engineering & Math)

## Education and an Inclusive Workforce

The MLSC awarded approximately \$417,000 to 10 programs focused on STEM education and diversity in the life sciences workforce during FY 2015. The grants reflect the MLSC's commitment to build a more inclusive life sciences workforce.

The ten organizations that received FY 2015 grants focus on different strategies for enhancing STEM education and diversity:

### **The Partnership: Diversity-Focused Professional Development Program for the Life Sciences (\$100,000)**

The Partnership is developing a robust diversity-focused professional development program tailored specifically for the life sciences industry. In concert with Biogen, the Partnership is convening leaders from the largest companies and organizations in the Massachusetts life sciences industry. A workshop will convene influential executives, senior leaders and human resources professionals from various corporations and industries in order to identify needs and solutions to increase diversity and inclusion within life sciences organizations and in leadership positions, and to pinpoint methods to retain these professionals. The Partnership will develop a program using its leadership development model based on the outcomes of the convening and analysis specific to the life sciences.

### **MedTech and BioTech Veterans Program (MVP) (\$50,000)**

Recognizing that there is a real need for talented employees in the growing medical device manufacturing industry, MVP was created to bring veterans and transitioning military professionals into medical device companies. Since 2010, 250 veterans and transitioning military have been able to participate in the program, and in 2014 the success of MVP compelled the founders to scale up to help a thousand veterans per year. The MLSC grant will assist MVP in further growing its program to assist Massachusetts veterans and transitioning military professionals with finding careers in medical device companies.

### **Boys & Girls Club of Worcester, Advancement of STEM Programs (\$50,000)**

The Boys & Girls Club of Worcester serves 6,000 children annually, with more than 350 boys and girls participating in programs each day. Having recently

completed a new, state-of-the-art facility, the Club now seeks to further these improvements by purchasing and installing new networked computer workstations and expanding STEM program offerings. MLSC funding will enable the purchase of over 30 networked computer workstations and also will support the expansion of the Club's STEM programming, specifically in robotics and digital arts. Additionally, the Club will use MLSC funds to expand gender-specific STEM offerings to expose more girls to STEM.

### **Just-A-Start: Evaluation of the Biomedical Careers Program (\$40,304)**

Just-A-Start Corporation (JAS) is a non-profit community development agency dedicated to building a better future through education and training. As part of their efforts, JAS provides the Biomedical Careers Program (BCP), which prepares low-to moderate-income graduates for entry level jobs in the biomedical industry, with a tuition-free, nine month, 760 hour program. This MLSC grant will support the comprehensive evaluation of Just-A-Start's BCP by the Center for Social Policy of the University of Massachusetts at Boston to assess the impacts of the program and to enhance its ability to plan for changes in the biomedical job market in the coming years.

### **The Possible Project: Project STEAM-related programming (\$40,000)**

The Possible Project (TPP) is a youth entrepreneurship program designed to close the opportunity gap and provide 21st century career skills to high school students. It was founded in 2010 by lifelong entrepreneurs Mark and Becky Levin in Cambridge, and plans to expand to additional sites nationally beginning with a second Massachusetts city in 2015. MLSC funding will support TPP's new 1,800 square foot Makerspace, which will bring cutting-edge manufacturing technology and digital arts to students.



### **Steps to Success (STS): Life Sciences LEGO Mindstorms Integration Project (\$33,282)**

STS' School Success Program provides after school education to approximately 270 students in grades 4 - 12, helping these young people to succeed and graduate from high school, well-poised to persist through post-secondary education. STS now seeks to integrate STEM learning into its program model. LEGO offers learning products and curricula designed to increase opportunities for students to meaningfully practice and master math, science, engineering and technology skills, thereby piquing their interest in these subjects. Steps to Success will utilize the MLSC grant to fund professional development training in LEGO robotics, as well as technology and personnel costs associated with program implementation.

### **Mount Holyoke College iDesign Workshop for Female Community College Students (\$30,000)**

MLSC funding for the iDesign summer workshop will be used to target and recruit 14 women attending Massachusetts community colleges who either have expressed an interest in STEM but may not have had previous exposure to design thinking, engineering, physics, and computer science or who are taking STEM courses. The design of this workshop will be modeled on a 4-credit, first-year seminar for Mount Holyoke College (MHC) undergraduates with no background in technology. All participants will receive a full scholarship, travel funds, and lunch.

### **The Springfield Urban League: Be the STEM: Academic and Career Mentoring Program (\$30,000)**

The Springfield Urban League (SUL) serves the African-American and other minority communities in Greater Springfield by advocating for and providing model services to enhance the academic and social development of young people and families, promoting economic self-sufficiency, and fostering racial inclusion and social justice. In fiscal year 2014, MLSC awarded SUL a grant for its Be the STEM

program aimed at engaging students in a group mentoring experience where they will have an opportunity to build personal, character and social skills, to improve academic progress that will help ensure future success, and to provide students with knowledge of various STEM disciplines and career opportunities. MLSC's additional funding will allow SUL to increase the program's existing services and to increase the number of program participants from 20 to 30 students, including students in the 7th and 8th grades.

### **MassMEDIC's MedTech IGNITE's Bay State Shadowing Program (\$25,000)**

The mission of MassMEDIC's MedTech IGNITE is to provide a focal point for entrepreneurs in early-stage Massachusetts medical device startups where they can seek guidance to foster success. Currently, new startups are spinning out of this program. The purpose of MLSC funding is to expand the shadowing program beyond Bay State Medical Center in Springfield and Boston Medical Center in the South End of Boston to include hospitals in the Partners Healthcare System, the UMass Medical Center in Worcester, and Lowell General.

### **Bentley University's Center for Women and Business (\$18,000)**

The MLSC is supporting Bentley University's Center for Women and Business through an \$18,000 grant for the Corporate Challenge, an initiative that engages employers that formally commit to growing and retaining women at all levels. The Center for Women and Business will work with its Corporate Challenge members to develop and manage a variety of programming that will include workshops, conferences, peer exchanges, and thought leadership on topics such as: gender intelligence, sponsorship and mentoring, closing the wage gap, men as allies/the role of men and fathers in women's advancement, measurement of progress, workplace flexibility, employee resource groups, and women's leadership development.

The MLSC will continue to seek additional opportunities to expand access to STEM education and to ensure an inclusive life sciences workforce in the fiscal year ahead.



# Industry and Job Creation

## The Life Sciences Tax Incentive Program

In FY 2015, the MLSC awarded over \$19 million in tax incentives to 11 life sciences companies under the MLSC's 2014 Life Sciences Tax Incentive program. The companies receiving tax incentive awards have committed to creating 1,075 new jobs in the Commonwealth during calendar year 2015.

The Life Sciences Act authorizes up to \$25 million in tax incentives each year for companies engaged in life sciences research and development, commercialization, and manufacturing. The primary goal of the program is to incentivize life sciences companies to create new long-term jobs in Massachusetts. Companies receiving incentives must commit to the creation of a specific number of net new jobs during the following calendar year and also to the retention of those jobs for a five-year period.

The 2014 round of the program offered 10 different incentives, which address the significant expenditures associated with the life sciences R&D cycle, high costs of translating research into commercially viable products, and substantial investment in manufacturing products.

A total of 37 companies applied for tax incentives in 2014. Details of the 11 tax incentive awardees are below:

### *Tax Incentives Awarded Under the MLSC's 2014 Life Sciences Tax Incentive Program*

Company	Location	Tax Incentive Amount Awarded	Jobs Committed
Baxter Healthcare Corporation	Cambridge	\$4,400,000	220
GE Healthcare Bio-Sciences Corp.	Marlborough	\$3,150,000	175
Alnylam Pharmaceuticals, Inc.	Cambridge	\$1,800,000	100
Amgen Inc.	Cambridge	\$1,800,000	100
Philips Electronics North America	Andover	\$1,800,000	100
Biogen	Cambridge	\$1,440,000	80
Merrimack Pharmaceuticals, Inc.	Cambridge	\$1,350,000	75
Alkermes, Inc.	Waltham	\$975,000	65
Synageva BioPharma Corp.	Lexington	\$900,000	60
Quest Diagnostics Incorporated	Marlborough	\$900,000	50
SMC Ltd	Sterling	\$500,000	50
<b>Total</b>		<b>\$19,015,000</b>	<b>1,075</b>



The MLSC takes its stewardship of these resources seriously and has built in strong accountability measures to ensure that the program has “teeth.” The MLSC carefully monitors the performance of companies that have received tax incentives to ensure compliance with the headcount requirements they are required to reach per their agreement with the Center. Headcount requirements must not only be met in the year following receipt of the award, but also maintained for the following five years. As part of the MLSC’s agreements with awardees, recipients of tax incentives are required to report job creation results to the Center by the end of the calendar year. Under the Life Sciences Act, the Department of Revenue has the authority to recover or “claw back” incentives from companies that the MLSC determines will not meet the minimum job creation threshold in their tax incentive agreement.

Some awardees have declined their awards due to changes in their business or general economic conditions. Some awardees also have determined that they were unlikely to reach their job creation commitment under the statutory guidelines and opted to voluntarily terminate their agreements, either by foregoing taking the tax benefits at all or by returning the benefits to the Commonwealth if they had already received them. Since inception, the MLSC has decertified two awardees for not achieving the statutory thresholds. A total of 24 active\* companies have received two or more active awards, illustrating their continued commitment to growing their headcount in the Commonwealth.

In FY 2015, awardees from the 2009 through 2013 tax programs were required to report their headcount as of December 31, 2014. As of December 31, 2014, reporting awardees from the 2009 through 2013 programs had hired and maintained 5,847 employees, representing a 156% percent attainment of their commitment.

As of June 30, 2015, there were 78 active awards from the 2010 through 2013 program years, with a combined commitment of fulfilling or maintaining 3,046 new hires under the program. The awardees from the 2009 program completed\*\* their 5 year term on December 31, 2014 and no future reporting is required.

The results of these awards will be reported to the MLSC in January 2016. To date, the Tax Incentive Program has resulted in combined net new hire commitment or actual new hires of 4,540 jobs among active and completed awards.

## Summary of the Tax Incentive Program from Inception to June 30, 2015

Program Year	Number of Awards Provided	Dollar Amount of Awards Provided	Number of Active* Awards as of June 30, 2015	Dollar Amount of Active* Awards as of June 30, 2015
2010	24	\$24,390,292	12	\$17,166,186
2011	26	\$20,340,884	18	\$12,208,937
2012	24	***\$22,992,583	20	\$18,920,583
2013	32	\$24,498,182	28	\$22,706,133
2014	11	\$19,015,000	11	\$19,015,000
<b>Total Active</b>	<b>117</b>	<b>\$111,236,641</b>	<b>89</b>	<b>\$90,016,839</b>
Program Year	Number of Awards Provided	Dollar Amount of Awards Provided	Number of Completed** Awards as of June 30, 2015	Dollar Amount of Completed** Awards as of June 30, 2015
2009 Completed	26	\$24,420,000	10	\$13,049,260
<b>Total</b>	<b>143</b>	<b>\$135,656,941</b>	<b>99</b>	<b>\$103,066,099</b>

\*Active awards indicate that the recipient company is still within the five year period under their tax incentive agreement.

\*\*Completed awards indicate that the recipient company has completed their five year requirement under their tax incentive agreement.

\*\*\*In FY 2012, Shire HGT, Inc., of Lexington received an additional \$3.5 million in tax incentives under an existing tax commitment by the Commonwealth.



# Building Partnerships

The MLSC created its international programs based on our belief that knowledge creation occurs worldwide, and that global collaboration between life sciences organizations will accelerate scientific and commercial breakthroughs and fuel economic development.

## International Collaborative Industry Program (ICIP)

In FY 2015, the MLSC successfully completed its second round of the International Collaborative Industry Program (ICIP). ICIP creates the opportunity for Massachusetts companies to apply for matching grants (\$75,000 minimum to \$400,000 maximum) to fund collaborative R&D projects with companies in international partner regions. The second round of ICIP included six partner regions:

- Alsace (France)
- Quebec (Canada)
- Victoria (Australia)
- Wallonia (Belgium)
- Israel
- Medicon Valley (Sweden and Denmark)

Collaborative projects selected for awards are funded collectively: each of the awarded companies contributes funding, the MLSC provides a grant to the Massachusetts partner company and the collaborating region provides a grant to its regional partner company.

Submitted applications were jointly reviewed by the MLSC SAB and expert reviewers in our partner geographies.

In March 2015 the MLSC Board of Directors approved awards to four Massachusetts companies, totaling \$1.6 million dollars:

### ICIP Program Awards

Company	Location	Amount Awarded	In Partnership With
Q State Biosciences, Inc.	Cambridge	\$400,000	Anagenesis Alsace, France
Lantern Pharma, Inc.	Cambridge	\$400,000	Oncology Venture Denmark
Triton Systems, Inc.	Chelmsford	\$400,000	Grey Innovation Victoria, Australia
KEW Group Inc.	Cambridge	\$400,000	DiaTech Technology Quebec, Canada



## The Universal Partnerships Program (UP)

The Universal Partnerships Program (UP) reflects the MLSC's commitment to further strengthen Massachusetts's global leadership position in the life sciences, to drive future economic growth and employ new models of collaboration.

UP provides grant funding for R&D collaborations between Massachusetts companies and partners that can include industry, academic institutions, hospitals, or research institutes in any non-U.S. geography. Grants can range from \$50,000 to \$200,000.

Applications for UP were accepted throughout the year and an ongoing review allowed for a streamlined decision process. A competitive proposal focused on a well-articulated milestone within an R&D project with a goal of completion within roughly one year.

In FY 2015 the MLSC Board of Directors approved awards to seven Massachusetts companies, totaling more than \$1.3 million dollars. Those awardees are below.

### UP Program Awards

Company	Location	Amount Awarded	In Partnership With
Avaxia Biologics Inc.	Lexington	\$200,000	Delphi Genetics / Wallonia Belgium
Matrivax R&D Corporation	Boston	\$190,000	Synermore Biologics/Taiwan
Riparian Pharmaceuticals	Boston	\$200,000	Hybrigenics Services / France
PNP Research Corporation	Drury	\$198,400	BBI Solutions / UK
Barrett Technology Inc.	Newton	\$200,000	SenseGraphics / Sweden
Cam Med LLC	West Newton	\$175,000	Dongguan Xindingyuan Jidian / Guangdong China
Felicitex Therapeutics Inc.	Newton	\$200,000	Selvita / Poland

## The International Partnership Assistant Portal (IP-ap)

In November 2012, the MLSC launched the International Partnership Assistance Portal (IP-ap), a tool that enables international and Massachusetts companies to explore potential partnerships 24/7/365. The portal also enables Massachusetts companies to pursue partnerships with one another. The MLSC hosts IP-ap as a free, password-protected, cloud-based portal. Since its launch, IP-ap has become a growing global database of potential partners from a range of therapeutic areas and industry sectors within the life sciences.

At the close of FY 2015, the IP-ap database contained 271 company profiles (168 International and 103 Massachusetts) and dozens of profiles from international and local life sciences-related agencies and institutions. International companies listed in the portal represent 26 countries and five continents. Massachusetts companies from more than 43 cities and towns have registered their business profiles in the portal.



# A New Horizon: Galactic Partnerships

The MLSC has always prided itself on the unique partnerships it participates in, both domestically and internationally, but in FY 2015, we took our collaborations to literally new heights. Partnering with the Center for the Advancement of Science in Space (CASIS), the MLSC announced two new competitions granting awardees the opportunity to have research conducted on the International Space Station (ISS). The partnership was conceived to take advantage of the ISS R&D Conference taking place in Boston in early July, 2015 where the winners of each competition were announced.

The first program, the "Galactic Grant Competition" offered Massachusetts-based life sciences companies access to the distinct attributes of the ISS research platform. The microgravity environment on the ISS has profound and unique effects on biological phenomena and can enable discoveries with terrestrial applications, including drug discovery, development, delivery, and diagnostics. The other competition, the "Space Station STEM Challenge" was created for Massachusetts middle school students. Teams composed of public middle school students competed to design, build and send their own original research experiments to the ISS, while a runner up team would conduct ground-based experiments as a ground-based control.

At the ISS R&D Conference, alongside Governor Charlie Baker, the MLSC announced the winners of the Galactic Grant Competition. Cambridge based Zaiput Flow Technologies and Nanobiosym Inc. were awarded a total of \$500,000 by the MLSC, which was leveraged by up to \$7.4 million each with support from CASIS to fly their projects up to the station, conduct their projects on station, and bring the experiments back to earth.

Astronaut Cady Coleman helped announce the winners of the \$50,000 Space Station STEM Challenge on day three of the ISS R&D Conference. Talbot Middle School in Fall River, MA was the winner of the Space Station STEM Challenge and Collins Middle School in Salem, MA was the runner up. Talbot will receive a flight-based NanoLab, and a grant in the amount of \$6,000 to purchase materials to support the experiment. Collins will receive \$5,000 to conduct the same experiment on the ground for comparison of results.



# Education and Outreach Partnerships

During FY 2015, the MLSC awarded a \$50,000 grant to the Prostate Health Education Network (PHEN) for an evaluation of the Impact of PHEN's Prostate Health Education and Awareness Activities and an Expansion of PHEN Programs to Worcester County.

Founded in Massachusetts in 2003, PHEN is the leading nonprofit organization nationally focused on the urgent and unmet prostate health education and awareness needs of African-American men, who die of prostate cancer at a rate that is 2.5 times greater than that of all other men. Lack of awareness and knowledge about the disease are major contributing factors to this health crisis. PHEN's educational outreach activities, which focus on information about risk level, screening guidelines, treatment options and survivorship issues, provide knowledge that is critical to surviving prostate cancer and also help remove the long-standing fear, silence and stigma surrounding the disease in the African-American community.

PHEN plans to use a portion of MLSC's grant to fund the evaluation of the above-described education and outreach activities. PHEN will use MLSC funding to conduct two rigorous, scientific evaluation processes, gathering data on each of its four programs (Monthly Support Groups, PHEN Survivor Network, Father's Day Rally and Educational Symposia) to determine the effect PHEN initiatives have had on increasing prostate health education and awareness.

Having made great strides in reaching out to and educating the African-American community in the Boston metropolitan area, PHEN also will use a portion of MLSC's grant to extend its outreach to Worcester, which has the second largest African-American population in the Commonwealth. In partnership with the University of Massachusetts Medical School, MLSC funds will be used to create a new support group and PHEN Survivor Network in Worcester to enable PHEN to reach approximately 40,000 additional African-American Massachusetts residents.

## Massachusetts Clinical Innovation Gateway

During the 2015 BIO International Convention, the Massachusetts Life Sciences Center (MLSC) joined the Conference of Boston Teaching Hospitals (COBTH) and the University of Massachusetts Memorial Medical Center to announce the launch of the Massachusetts Clinical Innovation Gateway. The new web portal will allow life sciences companies from around the world to seek opportunities to partner with Massachusetts Academic Medical Centers (AMCs) on research and clinical initiatives.

The MLSC and COBTH have developed a form and process to triage partnership requests from interested life sciences companies. Companies seeking to explore partnership opportunities with Massachusetts AMCs can complete the online form, which will be sent to representatives from each of the AMCs for review and consideration. Participating AMCs include:



Cambridge Health Alliance  
A COMMUNITY OF CARING



Massachusetts  
Eye and Ear  
Infirmary



# Participation in Global Conferences and Trade Shows

In FY 2015, the MLSC was represented at key international life sciences conferences in Japan, Germany, Korea, China, Switzerland and Scotland. In addition, several key industry conferences were held within the United States, including multiple conferences in Boston as well as in New York and Philadelphia. Through its participation in conferences and trade shows, the MLSC has established strategic relationships with industry, government officials, and academic institutions in many regions of the world creating business development opportunities that would otherwise not be available. These relationships, and those established in previous years, have created job growth in Massachusetts through the expansion and relocation of international companies to the Commonwealth as well as opportunities abroad for Massachusetts companies. Coupled with funding through the MLSC's international collaboration programs, these relationships are helping the Commonwealth maintain its global leadership in the life sciences while playing an expanded role in the global economy.

## BIO International Convention 2015

The 2015 BIO International Convention took place in Philadelphia, PA, on June 16-18. Once again, Massachusetts had strong representation from industry, academia, and government within the Massachusetts Pavilion, which drew heavy traffic throughout the show. Within the Massachusetts Pavilion a press announcement, four panel discussions, and a well-attended networking session took place. State and local officials participated in more than 15 business development meetings with domestic life sciences companies and met with more than a dozen international company representatives to strengthen relationships and collaborations, and explain why Massachusetts is a great place to do business. The Chinese BIO delegation gathered for a photo and networking opportunity within the pavilion, and as always, the Massachusetts networking reception was a well-attended event.

During BIO, the MLSC announced three company wins for Massachusetts: SIRION Biotech, headquartered in Germany, an expansion win that is working with the MLSC to locate lab and office space in Massachusetts; and Tarogenyx and Xcovery, related companies with offices in Florida, announced their expansion into Needham.



# Staying Connected

The MLSC's communications and marketing program keeps stakeholders and the general public informed about the MLSC's investment of public dollars, promotes public accountability for the MLSC's progress in accomplishing its mission, and provides ongoing updates and information exchange with the life sciences community in order to encourage its involvement and input. Communication and outreach have been integral to the MLSC's success in attracting a robust and diverse pool of applicants for MLSC programs.


## During FY 2015



The MLSC grew its email contact list from 5,500 to 6,000



The MLSC website was viewed over 225,000 times. Visitors used the site as both a hub for information and a portal for submitting applications to MLSC programs.



The MLSC grew its Twitter follower base from 1,600 to more than 2,700



The MLSC averaged more than 800 impressions (views) on LinkedIn



The MLSC grew its Facebook fans from 150 to 300

The MLSC also continued its monthly television segment on New England Cable News (NECN), sharing updates on MLSC activities and important news from the state's life sciences community.

In FY 2015 the MLSC maintained a high-level of visibility in the media, including more than 2,300 media mentions.

During FY 2015, MLSC staff participated as presenters, speakers, or panelists at more than 60 public events.



# The Way Forward

Through seven years of strategic investment Massachusetts has become the clear global leader in life sciences, and a magnet for life sciences companies large and small from all over the world that want to be a part of the world's leading ecosystem for life sciences innovation and growth. Over the coming year we will continue to work with companies from across the globe to facilitate their arrival and expansion in Massachusetts, bringing new jobs, technologies and partnership opportunities with them.

This past year has brought a lot of change for the MLSC, including new leadership on the state level and at the Center. We are thankful to founding President & CEO Susan Windham-Bannister, Ph.D., for her vision and leadership, and to Acting President & CEO Mike Kennealy for his stewardship of the Center during a period of transition. We are excited to welcome our new President & CEO, Travis McCready.

The state budget provides for a FY 2016 investment fund appropriation of \$10 million, contingent on the State Comptroller's declaration of a consolidated net surplus for FY 2015. The MLSC appreciates, and is grateful to Governor Baker and his Administration, and the State Legislature under the leadership of Senate President Stan Rosenberg and Speaker of the House Robert DeLeo, for prioritizing this funding within the state budget. We look forward to working with these leaders and our partners in industry and academia as we continue to develop strategies for future growth.

The MLSC looks forward to delivering another high-impact year in FY 2016 as we continue to strengthen and expand Massachusetts' thriving life sciences ecosystem.



# Appendix A

## The Board of Directors of the Massachusetts Life Sciences Center as of June 30, 2015

### **Jay Ash, Co-Chair**

Secretary, Executive Office of Housing and Economic Development

### **Kristen Lepore, Co-Chair**

Secretary, Executive Office for Administration and Finance

### **Edward J. Benz, Jr., M.D.**

President and CEO, Dana-Farber Cancer Institute

### **Robert L. Caret, Ph.D.**

President, University of Massachusetts

### **Adelene Perkins**

Chair, President and Chief Executive Officer, Infinity Pharmaceuticals

### **Lydia Villa-Komaroff, Ph.D.**

Director and Retired Founding CEO, Cytonome/ST

### **Peter Parker, Ph.D.**

President, BioInnovation LLC, Co-Founder, LabCentral

# Appendix B

## Massachusetts Life Sciences Center Scientific Advisory Board as of June 30, 2015

### **Harvey Lodish, Ph.D., Chair**

Whitehead Institute for Biomedical Research and Professor of Biology and of Bioengineering, Massachusetts Institute of Technology

### **Hillel Bachrach**

Chairman, Viztek & UltraSPECT

### **James Barry, Ph.D.**

Executive Vice President and COO, Arsenal Medical

### **Kevin J. Bitterman, Ph.D.**

Principal, Polaris Venture Partners

### **Dalia Cohen, Ph.D.**

Head of Research, Beryllium

### **James J. Collins, Ph.D.**

Professor of Biomedical Engineering, Massachusetts Institute of Technology

### **John M. Collins, Ph.D.**

Chief Operating Officer, Center for Integration of Medicine & Innovative Technology (CIMIT)

### **Robert D'Amato, M.D., Ph.D.**

Judah Folkman Chair in Surgery and Director, Center for Macular Degeneration Research, Children's Hospital, Boston

### **T. (Teo) Forcht Dagi, M.D.**

Former Partner, HLM Venture Partners

### **Glenn R. Gaudette, Ph.D.**

Associate Professor, Biomedical Engineering, Worcester Polytechnic Institute

### **José-Carlos Gutiérrez-Ramos, Ph.D.**

CEO, Synlogic

### **Andrew Jay, DMD**

Fund Head, Healthcare Fund, Siemens Venture Capital

### **Rick Jones, MD**

Co-COO, Broadview Ventures

### **Henry Kay**

U.S. Partner, Medica Venture Partners

### **Dale Larson**

Director of Biomedical Systems, Draper Laboratory

### **Alison Lawton**

Board Member, Cubist Pharmaceuticals & Verastem

### **Judith Lieberman, Ph.D., M.D.**

Senior Investigator, Immune Disease Institute, Children's Hospital Boston and Professor of Pediatrics, Harvard Medical School

### **Lita L. Nelsen**

Director, Technology Licensing Office, Massachusetts Institute of Technology

### **Barbara Osborne**

Professor of Veterinary and Animal Sciences, University of Massachusetts Amherst

### **Carmichael Roberts, Ph.D.**

Partner, North Bridge Venture Partners

### **Frederick J. Schoen, M.D., Ph.D.**

Executive Vice-Chairman, Department of Pathology at Brigham and Women's Hospital

### **Lauren Silverman, Ph.D.**

Managing Director, Novartis Option Fund

### **Alan E. Smith, Ph.D.**

Former Chief Scientific Officer, Genzyme Corporation

### **Alison Taunton-Rigby, Ph.D.**

Co-founder, CEO and Director, RiboNovix, Inc.

### **Guillermo Tearney, M.D., Ph.D.**

Professor of Pathology, Harvard Medical School

### **David Walt, Ph.D.**

Robinson Professor of Chemistry and Howard Hughes Medical Institute Professor, Tufts University School of Medicine

# Appendix C

## 2014-2015 Internship Challenge Host Companies

Comapny	Location	Company	Location
A Chemtek, Inc.	Worcester	Blue Sky Biotech, Inc.	Worcester
AB Biosciences, Inc.	Boston	Blue Stream Laboratories, Inc.	Cambridge
Abazyme LLC	Cambridge	Boston Device Development Inc.	Newton
Accelaron Pharma	Cambridge	Boston MedTech Advisors	Dedham
Acetylon Pharmaceuticals, Inc.	Boston	Boston Micromachines Corporation	Cambridge
Addgene, Inc.	Cambridge	Boyd Technologies Inc.	Lee
Advanced Instruments, Inc.	Norwood	Brain Backups	Everett
Advanced Radiation Therapy	Tyngsboro	Cambridge Biomedical Inc.	Boston
Advanced Research and Development	Lexington	Catapult Product Development, Inc.	Waltham
AdvanDx Inc.	Woburn	Cell Assay Innovations, Inc.	Beverly
Agilux Laboratories	Worcester	Celldex Therapeutics	Needham
Agrivida, Inc.	Medford	CELLTREAT Scientific Products, LLC	Shirley
Akrivis Technologies, LLC	Cambridge	CeQur Corp.	Marlborough
Alacrita LLC	Cambridge	Boxford	Cambridge
Albright Technologies	Leominster	Cerulean Pharma Inc.	Cambridge
Allurion Technologies	Wellesley	ChemGenes Corp.	Wilmington
Alzheimers Disease Center	Quincy	CIRTEC Medical Systems, LLC	East Longmeadow
Anderson Biotests, LLC	Bedford	CMC Consulting Boston, Inc.	Framingham
Anika Therapeutics	Bedford	Cocoon Biotech Inc.	Boston
Antagen Pharmaceuticals, Inc.	Boston	Collegium Pharmaceutical, Inc.	Canton
Aphios Corporation	Woburn	Constant Therapy Inc.	Lexington
Arch Therapeutics, Inc.	Wellesley	Constellation Pharmaceuticals	Cambridge
Arsenal Medical	Watertown	CONTINUUS Pharmaceuticals, Inc.	Woburn
Artaic	Boston	Corbus Pharmaceuticals, Inc. (fka JB Therapeutics)	Norwood
Arteriocyte Medical Systems	Hopkinton	Court Square Group, Inc.	Springfield
Artietis Corporation	Boston	Courtagen Life Sciences	Woburn
Artisan Consulting	Waltham	Covaris Inc.	Woburn
Asaman Inc.	Abington	CRYOOCYTE INC.	Allston
Atlantic Lab Equipment LLC	Salem	CryoXtract Instruments, LLC	Arlington
Avaxia Biologics, Inc.	Lexington	CSA Medical, Inc.	Lexington
Averica Discovery Services	Worcester	CuriRx Inc.	Wilmington
Bach Pharma, Inc.	North Andover	Curoverse, Inc.	Boston
Baylis Medical	Burlington	Cytonome/ST, LLC	Boston
Bethcare, Inc.	Boston	Dermal Photonics Corporation	Danvers
Bio2 Technologies, Inc.	Woburn	Detector Technology, Inc.	Palmer
BIOBASE Corporation	Beverly	DiscX, LLC	Waltham
Bio-Detail Corporation	Worcester	DNA Medicine Institute	Cambridge
Biomedical Research Models Inc.	Worcester	Editas Medicine, Inc.	Cambridge
BioScale, Inc.	Lexington	eGenesis Inc.	Boston
BioSensics LLC	Cambridge	Ekam Imaging, Inc.	Boston
BioVolutions Inc.	Woburn	Endodynamix, Inc.	Salem
Blend Therapeutics	Watertown	Endosim LLC	Hudson
Blue Ocean Biomanufacturing, Inc.	Worcester	enEvolv, Inc.	Cambridge

# Appendix C

## 2014-2015 Internship Challenge Host Companies

Company	Location	Company	Location
Enumeral Biomedical, Corp.	Cambridge	IonSense, Inc.	Saugus
Environmental Health & Engineering Inc.	Needham	IPFINI, Inc.	Sudbury
EpigenDx, Inc.	Hopkinton	iQuartic Inc.	Brookline
Essential Life Solutions Ltd.	Stoughton	iSpecimen Inc.	Lexington
Etiometry, Inc.	Boston	Jounce Therapeutics	Cambridge
Eutropics Pharmaceuticals Inc.	Cambridge	KBioBox Inc.	Worcester
Everost, Inc.	Sturbridge	KBioSim Inc.	Worcester
Excellims Corp.	Acton	KeraFAST, Inc.	Boston
Extend Biosciences Inc.	Cambridge	Kesin Medicine, Inc.	Lowell
FastCAP SYSTEMS Corporation	Boston	Labminds	Boston
First Light Biosciences	Bedford	Lariat Biosciences, Inc.	Beverly
Five Star Manufacturing Inc.	New Bedford	LaVoie Strategic Communications Group	Waltham
FloDesign Sonics, Inc.	Wilbraham	LayerBio	Arlington
Focused Genomics (dba Parabase Genomics)	Boston	Life Science Nation	Boston
Fractyl Laboratories Inc.	Waltham	Little Sparrows Technologies	Winchester
G & F Medical, Inc	Danvers	Mayly Inc.	Brighton
Gecko Health Innovations	Cambridge	MedPanel, LLC	Cambridge
Gen9, Inc.	Cambridge	Medrobotics Corporation	Raynham
Genetic Services, Inc	Cambridge	Medtechna Incorporated	Dedham
Genocea Biosciences, Inc.	Cambridge	Microbiome Health Research Institute (OpenBiome)	Medford
GenoSpace, LLC	Cambridge	Microbiotix, Inc.	Worcester
Genty LLC	Somerville	Micro-Leads, Inc.	Boston
GI Dynamics, Inc.	Lexington	Microtest Laboratories, Inc.	Agawam
Giner, Inc.	Newton	Mouse Specifics	Framingham
Ginkgo BioWorks, Inc.	Boston	MX Orthopedics	Billerica
Grove Instruments	Worcester	Myomo, Inc.	Cambridge
Guided Surgery Solutions	Wellesley	Nemucore Medical Innovations, Inc.	Worcester
Halloran Consulting Group, Inc.	Waltham	Neo-Advent Technologies, LLC	Littleton
HelixBind, Inc.	Marlborough	New England Peptide Inc.	Gardner
HepatoChem Inc.	Beverly	Nexcelom Bioscience LLC	Lawrence
HighRes Biosolutions Inc.	Woburn	NexGen Arrays, LLC	Boston
Hstar Technologies Co.	Cambridge	NinePoint Medical, Inc.	Cambridge
Human Metabolome Technologies Inc.	Boston	Nivarta, Inc.	Cambridge
Hybrigenics Corporation	Cambridge	NKT Therapeutics Inc.	Waltham
Incite Advisors, Inc.	Auburn	Nonspec	Carlisle
InCrowd, Inc.	Cambridge	Northeast Biomedical, Inc.	Tyngsboro
InfoBionic	Lowell	Nuclea Biotechnologies, Inc.	Pittsfield
Infraredx, Inc.	Burlington	Olaris Therapeutics, Inc.	Cambridge
Institute for Pediatric Innovation	Cambridge	Oncovision, Inc.	Boston
Interactive Motion Technologies, Inc.	Watertown	OpenClinica LLC	Waltham
invicRO, LLC	Boston	Optimum Technologies, Inc.	Southbridge
iOmics Corporation	Worcester	ORIG3N, Inc.	Boston

# Appendix C

## 2014-2015 Internship Challenge Host Companies

Company	Location	Company	Location
Orthotics & Prosthetics Labs	Springfield	Sano LLC	Wellesley
Parcell Laboratories, LLC	Natick	Sathguru Inc.	Boston
Pavoda Inc.	Sudbury	SBH Sciences, Inc.	Natick
iQuartic Inc.	Brookline	Securus Medical Group, Inc.	Beverly
Phosphorex, Inc.	Hopkinton	Selecta Biosciences, Inc.	Watertown
pION INC.	Woburn	Seminex Corporation	Peabody
PixarBio Corp.	Medford	Senscio Systems, Inc.	Boxborough
Podimetrics, Inc.	Somerville	Sentien Biotechnologies, Inc.	Medford
Polycarbon Industries (PCI Synthesis, Inc)	Newburyport	Seventh Sense Biosystems, Inc.	Cambridge
Portal Instruments, Inc.	Cambridge	Shaser Bioscience	Lexington
Precision Fabricators Ltd.	Stoughton	Speech Technology and Applied Research	Bedford
PrepMD	Braintree	Sproxil, Inc.	Cambridge
Pressure BioSciences, Inc.	South Easton	STC Biologics, Inc.	Cambridge
Privo Technologies	Cambridge	Teleos Therapeutics	Medford
Project Lever LLC	Cambridge	Tetraphase Pharmaceuticals, Inc.	Watertown
Proveris Scientific Corporation	Marlborough	Thermedical, Inc.	Waltham
Putnam Associates	Burlington	Tissue Solutions, LLC	Marblehead
Q-State Biosciences, Inc.	Cambridge	Ubiqi Health, Inc.	Somerville
Quad Technologies	Beverly	Union Biometrica, Inc.	Holliston
Quanterix Corporation	Lexington	VasoTech, Inc.	Lowell
Ra Pharmaceuticals	Cambridge	Vaxess Technologies, Inc.	Cambridge
RainDance Technologies, Inc.	Billerica	Veritas Genetics Inc.	Beverly
RAN Biotechnologies, Inc.	Beverly	Viatar LLC	Lowell
RaNA Therapeutics, Inc.	Cambridge	VitaThreads, LLC	Worcester
Respiratory Motion, Inc.	Waltham	Vivonics, Inc.	Waltham
Riparian Pharmaceuticals	Boston	Windgap Medical, Inc.	Somerville
Robie Device Group, LLC	North Andover	World Care Clinical, LLC	Boston
Rogers Sciences Inc.	Beverly	X-BODY, Inc.	Waltham
Rowat Management Services LLC	Sherborn	X-Chem, Inc.	Waltham
SafePath Medical, Inc.	Lowell	Xenetic Biosciences	Lexington
Safety Partners, Inc.	Bedford	Xtal BioStructures Inc.	Natick
Sage Science Inc.	Beverly	ZS Genetics, Inc.	Wakefield
Sample6 Technologies, Inc.	Cambridge		

# Appendix D

## List of Active Certified Life Sciences Companies as of June 30, 2015

<b>Company</b>	<b>Location</b>	<b>Company</b>	<b>Location</b>
3Derm Systems, Inc.	Cambridge	Eutropics Pharmaceuticals, Inc.	Cambridge
908 Devices, Inc.	Boston	Excellims Corporation	Acton
Aegerion Pharmaceuticals, Inc.	Cambridge	Extend Biosciences Inc.	Cambridge
AesRx, LLC	Newton	Felicitex Therapeutics Inc.	Newton
Akita Innovations, Inc.	North Billerica	Foundation Medicine, Inc.	Cambridge
Alcyone Lifesciences, Inc.	Concord	GE Healthcare Bio-Sciences Corp.	Marlborough
Alkermes, Inc.	Waltham	Grove Instruments, Inc.	Worcester
Allurion Technologies, Inc.	Wellesley	Guided Surgery Solutions, LLC	Wellesley
Alnylam Pharmaceuticals, Inc.	Cambridge	Hepatochem, Inc.	Cambridge
Amgen Inc.	Cambridge	Immunexcite, Inc.	Lexington
Aquinnah Pharmaceuticals, Inc.	Cambridge	InsomniSolv, Inc.	Beverly
Arch Therapeutics, Inc.	Wellesley	Instrumentation Laboratory Company	Bedford
Avaxia Biologics, Inc.	Lexington	inviCRO, LLC	Boston
Barrett Technology Inc.	Newton	Ironwood Pharmaceuticals, Inc.	Cambridge
Baxter Healthcare Corporation	Cambridge	Jounce Therapeutics, Inc.	Cambridge
Bind Biosciences, Inc.	Cambridge	KEW Group Inc.	Cambridge
Bio2 Technologies, Inc.	Woburn	Lantern Pharma, Inc.	Cambridge
Biogen, Inc.	Cambridge	LayerBio, Inc.	Arlington
Bluebird Bio, Inc.	Cambridge	LeMaitre Vascular, Inc.	Burlington
Blueprint Medicines Corporation	Cambridge	Lightlab Imaging, Inc.	Westford
Boston Heart Diagnostics Corporation	Framingham	Lumicell Diagnostics, Inc.	Wellesley
Bruker Corporation	Billerica	Masy Systems, Inc.	Pepperell
Cam Med LLC	West Newton	Matrivax R&D Corporation	Boston
Cell Signaling Technology	Danvers	MCC Global Laboratories, Inc.	Beverly
Charm Sciences, Inc.	Lawrence	MedicaMetrix, Inc.	Wayland
Cognition Medical Corp.	Cambridge	Merrimack Pharmaceuticals, Inc.	Cambridge
Covaris, Inc.	Woburn	Micro-Leads, Inc.	Boston
Cre8MDI LLC	Cambridge	Micron Products, Inc.	Fitchburg
Cristcot Medical, Inc.	Sudbury	Moderna Therapeutics, Inc.	Cambridge
CSA Medical, Inc.	Lexington	Momenta Pharmaceuticals, Inc.	Cambridge
CytonomeST, LLC	Boston	Myomo, Inc.	Cambridge
DePuy Othopaedics, Inc.	Raynham	New England Biolabs, Inc.	Ipswich
EMD Millipore Corporation	Billerica	NinePoint Medical, Inc.	Cambridge
Energesis Pharmaceuticals Inc.	Cambridge	Nova Biomedical Corporation	Waltham
Enzymatics, Inc.	Cambridge	Nuclea Biotechnologies, LLC	Pittsfield
Epizyme, Inc.	Cambridge	NxStage Medical, Inc.	Lawrence

# Appendix D

## List of Active Certified Life Sciences Companies as of June 30, 2015

<b>Company</b>	<b>Location</b>
OMNlife science, Inc.	Taunton
Pall Corporation	Westborough
PAREXEL International Corporation	Lowell
Parsagen Diagnostics, Inc.	Boston
PathMaker Neurosystems, Inc.	Boston
PerkinElmer, Inc.	Waltham
Pharmalucence, Inc.	Bedford
Philips Electronics North America	Andover
Platelet Biogenesis, Inc.	Chestnut Hill
PNP Research Corporation	Drury
Q State Biosciences, Inc.	Cambridge
Quanterix Corporation	Cambridge
Quest Diagnostics, Incorporated	Cambridge
Ra Pharmaceuticals, Inc.	Cambridge
Riparian Pharmaceuticals	Boston
Sample6 Technologies, Inc.	Boston
Sanofi-Aventis, Inc.	Cambridge
SBH Sciences, Inc.	Natick
Shire Human Genetic Therapies, Inc.	Lexington
SMC Ltd	Sterling
Strohl Medical Technologies, Inc.	Weymouth
Synageva BioPharma Corporation	Lexington
T2Biosystems, Inc.	Lexington
Triton Systems, Inc.	Chelmsford
uniQure, Inc.	Lexington
Valerion Thereapeutics, Inc.	Boston
Vaxess Technologies, Inc.	Cambridge
Windgap Medical	Somerville
Wolfe Laboratories, Inc.	Watertown
X4 Pharmaceuticals, Inc.	Belmont

**Massachusetts Life Sciences Center**  
(A Component Unit of the Commonwealth  
of Massachusetts)

Financial Statements and Reports Required  
for Audits Performed in Accordance with  
*Government Auditing Standards*

Years Ended June 30, 2015 and 2014

Preliminary and Tentative For Discussion Purposes Only

**Massachusetts Life Sciences Center**  
(A Component Unit of the Commonwealth of Massachusetts)

Financial Statements and Reports Required for Audits Performed in Accordance with  
*Government Auditing Standards*

Years Ended June 30, 2015 and 2014

---

C O N T E N T S

	<u>Page</u>
Independent Auditor's Report .....	1-2
Management's Discussion and Analysis (unaudited) .....	3-7
Financial Statements:	
Statements of Net Position .....	8
Statements of Revenues, Expenses and Changes in Net Position .....	9
Statements of Cash Flows .....	10
Notes to Financial Statements .....	11-25
Independent Auditors Report on Internal Control over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with <i>Government Auditing Standards</i> .....	26-27

## Independent Auditor's Report

To the Board of Directors of the  
Massachusetts Life Sciences Center  
Waltham, Massachusetts

### Report on the Financial Statements

We have audited the accompanying financial statements of the business-type activities of the Massachusetts Life Sciences Center (the "Center"), a component unit of the Commonwealth of Massachusetts, as of and for the years ended June 30, 2015 and 2014, and the related notes to the financial statements, which collectively comprise the Center's basic financial statements as listed in the table of contents.

### Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

### Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

### Opinion

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Massachusetts Life Sciences Center as of June 30, 2015 and 2014, and the changes in financial position and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

## **Other Matters**

### *Required Supplementary Information*

Accounting principles generally accepted in the United States of America require that the Management's Discussion and Analysis on pages 3–7 be presented to supplement the basic financial statements. Such information, although not a part of the basic financial statements, is required by the Governmental Accounting Standards Board who considers it to be an essential part of financial reporting for placing the basic financial statements in an appropriate operational, economic, or historical context. We have applied certain limited procedures to the required supplementary information in accordance with auditing standards generally accepted in the United States of America, which consisted of inquiries of management about the methods of preparing the information and comparing the information for consistency with management's responses to our inquiries, the basic financial statements, and other knowledge we obtained during our audit of the basic financial statements. We do not express an opinion or provide any assurance on the information because the limited procedures do not provide us with sufficient evidence to express an opinion or provide any assurance.

### **Other Reporting Required by Government Auditing Standards**

In accordance with *Government Auditing Standards*, we have also issued reports dated September 25, 2015 on our consideration of the Center's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of this report is to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on internal control over financial reporting or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity's internal control over financial reporting and compliance.

Boston, Massachusetts  
September 25, 2015

# Massachusetts Life Sciences Center

(A Component Unit of the Commonwealth of Massachusetts)  
Management's Discussion and Analysis (unaudited)  
Years Ended June 30, 2015 and 2014

---

As the Board of Directors of the Massachusetts Life Sciences Center (the "Center") we offer the following narrative overview and analysis of the financial activities of the Center for the fiscal years ended June 30, 2015, 2014 and 2013. This unaudited management discussion and analysis should be read in conjunction with the audited financial statements and the notes thereto, which follow this section.

The Center was created on June 24, 2006 in the Economic Stimulus Bill, Chapter 123, Section 24 of the Acts of 2006 and codified in the Massachusetts General Laws, Chapter 23I. The Center is a body politic and corporate. Exercise of the powers conferred by Chapter 23I is considered to be the performance of an essential governmental function. The purpose of the Center is to promote the life sciences industry within the Commonwealth of Massachusetts (the "Commonwealth"). It is tasked with investing in life sciences research and economic development initiatives. This work includes making financial investments in public and private institutions growing life sciences research, development and commercialization, as well as building ties between sectors of the Massachusetts life sciences community.

On June 16, 2008, the Life Sciences Act enacted by the Massachusetts Legislature was signed into law by Governor Deval Patrick. The Commonwealth committed to investing \$1 billion over a ten year period to create jobs, drive innovation and promote biomedical breakthroughs that improve people's lives. The Center is the steward of the \$1 billion and uses three statutory funding vehicles to achieve the Commonwealth's mission: the Life Sciences Investment Fund (the "Investment Fund"), the Capital Program and the Life Sciences Tax Incentive Program.

The Life Sciences Investment Fund is to be used in making appropriations, allocations, grants or loans to leverage development and investments in life sciences in Massachusetts. The Capital Program is for municipalities and institutions for buildings, equipment, upgrades to roads, sewer lines and other infrastructure that supports growth in the life sciences sector. The Life Sciences Tax Incentive Program allows the Center to award tax incentives to companies on behalf of the Department of Revenue (DOR) at every stage of development.

The Center is governed by a seven member Board of Directors (the "Board of Directors") consisting of: the Secretary of Administration and Finance or her/his designee; the Secretary of Housing and Economic Development or his/her designee; the president of the University of Massachusetts or his/her designee; and four members appointed by the Governor, one of whom is a physician licensed to practice medicine in Massachusetts and affiliated with an academic medical center, one of whom is a CEO of a Massachusetts-based life sciences corporation that is a member of the board of directors of the Massachusetts Biotechnology Council, one of whom is a researcher involved in the commercialization of biotechnology, pharmaceuticals or medical diagnostic products and one of whom has significant financial experience in the life sciences sector.

## Using the Financial Statements

The basic financial statements are prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") as promulgated by the Governmental Accounting Standards Board ("GASB"). The Center's financial statements are reported as a special purpose business type entity. The Center's annual report includes three basic financial statements: the statement of net position; the statement of revenues, expenses and changes in net position; and the statement of cash flows.

The statement of net position presents the financial position of the Center as of June 30, 2015 and 2014. It provides information about the nature and the amount of resources (assets), plus deferred outflows (as applicable), obligations (liabilities), plus deferred inflows (as applicable) and net position.

**Massachusetts Life Sciences Center**  
(A Component Unit of the Commonwealth of Massachusetts)  
Management's Discussion and Analysis (unaudited)  
Years Ended June 30, 2015 and 2014

---

Using the Financial Statements...continued

The statement of revenues, expenses and changes in net position presents the changes in net position over the course of the years ended June 30, 2015 and 2014. The change in net position may be useful in assessing whether the financial position improved or deteriorated for the year.

The statement of cash flows presents the cash activities segregated by four major cash flow categories; operating activities, noncapital financing activities, capital and related financing activities and investing activities. This statement may be useful in determining the changes in liquidity and in understanding how cash and cash equivalents were used during the years ended June 30, 2015 and 2014.

Financial Highlights

Fiscal year 2015 is the seventh year of the initiative and reflects a year of significant operating activities of the Center as grants were made both from the Investment Fund and Capital Programs and a sixth round of awards under the Life Sciences Tax Incentive Program were granted.

Investment Fund

Section 24 of Chapter 123 of the Acts of 2006 established the Massachusetts Life Sciences Investment Fund to be administered by the Center to finance its activities. The Life Sciences Act of 2008 contemplates an annual appropriation from the legislature totaling \$250 million over 10 years. The Investment Fund is also to be used to support the administrative expenses and investment in property and equipment of the Center.

The legislature appropriated \$11.4M million in fiscal year 2015, \$19.5 million in fiscal year 2014 and \$15 million in fiscal year 2013.

In fiscal year 2015, the Board of Directors authorized \$12.2 million in commitments as compared to \$4.6 million in fiscal year 2014 and \$6.4 million in fiscal year 2013. The commitments were for research grants, workforce development programs, and programs that support innovation in life sciences. The increase in fiscal year 2015 commitments from fiscal year 2014 is due to an increase in the number of programs offered in fiscal year 2015 and STEM related grants. The decrease in fiscal year 2014 commitments from fiscal year 2013 is due to one less program in fiscal year 2014 and one commitment that ended in fiscal year 2013. In fiscal year 2015, the Center incurred \$6.9 million of grant expense compared to \$4.4 million of grant expense in fiscal year 2014 and \$4.4 million in fiscal year 2013. The \$2.5 million increase of grant expense from fiscal year 2015 to 2014 is due to the addition of two new programs unveiled in fiscal year 2015: the Milestone Achievement Program and Universal Partnership program. The same level of grant expense from fiscal year 2014 to 2013 is due to a decrease in educational and workforce development expense and an increase in international programs. Remaining payment commitments as of June 30, 2015 on the outstanding grants are approximately \$14.1 million.

In fiscal year 2015, the Board of Directors authorized up to \$7 million for early stage company loans under the Life Sciences Accelerator Loan program for fiscal year 2016. The loan program provides working capital to early stage companies at a critical stage of development. From prior year authorizations, the Center awarded \$4 million in fiscal year 2015 and \$2.5 million in fiscal year 2014. Of the \$4 million in investment funds awarded in fiscal year 2015, none have been disbursed as of June 30, 2015.

## Massachusetts Life Sciences Center

(A Component Unit of the Commonwealth of Massachusetts)  
Management's Discussion and Analysis (unaudited)  
Years Ended June 30, 2015 and 2014

---

### Capital Programs

The Capital Program was created by the Life Sciences Act and is for municipalities and institutions for buildings, equipment, upgrades to roads, sewer lines and other infrastructure that supports growth in the life sciences sector. The Life Sciences Act provides for \$500 million to the Capital Program over 10 years. The Capital Program is funded by the Commonwealth of Massachusetts. In fiscal year 2015, the Center entered into 16 new commitments totaling \$27 million. In fiscal year 2015, the Center incurred \$74.8 million of grant expense compared to \$47.7 million of grant expense in fiscal year 2014 and approximately \$52.4 million in fiscal year 2013. The increase in fiscal year 2015 from 2014 is due to timing of new capital projects started in fiscal year 2015 and increasing expenditures for existing projects. The decrease in fiscal year 2014 from 2013 is due to payments for qualifying expenses relating to grants awarded in prior years together with new fiscal year 2014 projects and the delay of \$11.4M of expense for one project.

The Life Sciences Act also provides for a Life Sciences Education fund for providing grants for purchasing or leasing equipment to train students in life sciences and research. In fiscal year 2015, the Center made 44 grants under the program totaling nearly \$3.8 million and incurring no expense in fiscal year 2015. In fiscal year 2014, the Center made 35 grants under the program totaling nearly \$3.3 million incurring \$3 million expense in fiscal year 2015. In fiscal year 2013, the Center made 31 grants for under the program totaling nearly \$3.2 million and incurring expense of \$1.6 million in fiscal year 2014.

The Life Sciences Act also provides for a small business matching grant fund under the Capital Program. Under the program companies that have received Phase II or later small business innovation research ("SBIR") grants can receive up to \$500,000 in grants from the Center to assist the awardee with commercializing their product. The program was not offered in fiscal year 2015 or 2014. In fiscal year 2015, the Center recovered \$109,444 from a prior awardee.

### Life Sciences Tax Incentive Program

The Life Sciences Tax Incentive Program was created by the Life Sciences Act and allows the Center to award tax incentives to companies at every stage of development on behalf of the DOR. The Center has the ability to award ten different tax incentives with a cumulative cap of \$25 million per year for 10 years. The tax incentives have no financial impact on the Center. The Center awarded \$19 million to 11 companies in fiscal year 2015, \$24.4 million to 32 companies in fiscal year 2014 and \$23 million to 24 companies in fiscal year 2013.

### Investment Income

Investment income in fiscal year 2015 was \$90,100 compared to \$67,600 compared in fiscal year 2014 and \$58,000 in fiscal year 2013. Investment income relates to interest earned throughout the fiscal year on the Center's cash and cash equivalent balance. The increase in fiscal year 2015 from fiscal year 2014 is due to higher balances. The increase in fiscal year 2014 from fiscal year 2013 is due to higher balances. The decrease in fiscal year 2013 from fiscal year 2012 is due to lower interest rates.

**Massachusetts Life Sciences Center**  
(A Component Unit of the Commonwealth of Massachusetts)  
Management's Discussion and Analysis (unaudited)  
Years Ended June 30, 2015 and 2014

---

Administrative Expenses and Investments in Property and Equipment

In accordance with the Act, administrative expenses and purchases of property and equipment are provided by the Investment Fund. In fiscal year 2015, the Center incurred approximately \$3.5 million of administrative expenses and purchases of property and equipment. In fiscal year 2014 and 2013, the Center incurred approximately \$3.2 million and \$2.7 million of administrative expenses, respectively. The increase in expenditures in fiscal year 2015 from fiscal year 2014 is due to higher staffing costs related to new hires, communications programs and purchases of property and equipment. The increase in expenditures in fiscal year 2014 from fiscal year 2013 is due to higher staffing costs related to new hires, communications programs and purchases of property and equipment. The increase in expenditures in fiscal year 2013 from fiscal year 2012 is due to higher staffing costs related to new hires and communications programs. For the fiscal years ended June 30, 2015, June 30, 2014 and June 30, 2013, the headcount of the Center was nineteen, nineteen, and fourteen, respectively.

Liquidity of the Investment Fund

From inception through June 30, 2015, the Investment Fund has received appropriations from the Commonwealth of \$115.9 million. In addition, the Center has earned investment income of approximately \$2.3 million and collected approximately \$8.1 million through loan repayments, sponsorship, insurance proceeds, and corporate consortium revenues for total inflows of approximately \$126.3 million. The Center reserves all the funds required for a grant or loan commitment at the time of the Board of Directors' authorization. From inception through June 30, 2015, the Center has disbursed or reserved approximately \$119.4 million resulting in approximately \$6.9 million of available funds as of June 30, 2015.

Budgets and Appropriations

Annual operating budgets are developed on a basis consistent with GAAP. The Center's annual operating budgets are developed through an internal process and reviewed and modified as appropriate by the Center's executive management. The annual operating budget is presented to the Center's Board of Directors for final approval and adoption. The budget approved by the Board is used for purposes of management accountability. The budget passed by the Board is not, however, considered a legally adopted budget and, therefore, is not presented as required, supplemental information to the financial statements.

**Massachusetts Life Sciences Center**  
(A Component Unit of the Commonwealth of Massachusetts)  
Management's Discussion and Analysis (unaudited)  
Years Ended June 30, 2015 and 2014

Financial Summary

The following summarizes the Statement of Net Position and Revenue, Expenses and Changes in Net Position for fiscal years 2015, 2014 and 2013.

**Statement of Net Position**

	June 30, 2015	June 30, 2014	June 30, 2013
<b>Assets</b>			
Current assets	\$ 91,926,541	\$ 76,006,642	\$ 61,263,866
Assets held on behalf of Neuroscience Consortium	872,177	1,891,305	1,750,143
Assets held in escrow	-	11,400,000	-
Noncurrent assets	5,912,333	5,058,350	4,024,924
Capital assets	69,939	74,535	32,916
	<u>\$ 98,780,990</u>	<u>\$ 94,430,832</u>	<u>\$ 67,071,849</u>
<b>Liabilities</b>			
Current liabilities	\$ 51,967,916	\$ 36,474,679	\$ 31,405,701
Noncurrent liabilities	997,177	13,416,305	1,771,221
Total liabilities	<u>52,965,093</u>	<u>49,890,984</u>	<u>33,176,922</u>
<b>Net Position</b>			
Net investment in capital assets	69,939	74,535	32,916
Unrestricted	45,745,958	44,465,313	33,862,011
Total net position	<u>45,815,897</u>	<u>44,539,848</u>	<u>33,894,927</u>
	<u>\$ 98,780,990</u>	<u>\$ 94,430,832</u>	<u>\$ 67,071,849</u>

**Statements of Revenues, Expenses and Changes in Net Position**

**Revenues and Expenses**

Operating revenues	\$ 78,534,919	\$ 50,147,640	\$ 54,621,079
Operating expenses	<u>(88,738,758)</u>	<u>(59,070,293)</u>	<u>(62,985,939)</u>
Operating loss	(10,203,839)	(8,922,653)	(8,364,860)
Nonoperating revenues, net	90,119	67,574	58,209
Capital contributions, net	<u>11,389,769</u>	<u>19,500,000</u>	<u>15,000,000</u>
Increase in net position	<u>\$ 1,276,049</u>	<u>\$ 10,644,921</u>	<u>\$ 6,693,349</u>

**Massachusetts Life Sciences Center**  
(A Component Unit of the Commonwealth of Massachusetts)  
Statements of Net Position  
June 30, 2015 and 2014

	2015	2014
<b>ASSETS</b>		
Current assets:		
Cash and cash equivalents	\$ 13,861,738	\$ 16,857,374
Accounts receivable	251,749	270,320
Grant reimbursement receivable from Commonwealth of Massachusetts	46,462,821	32,335,218
Loans receivable, net	150,000	-
Interest receivable, net	70,999	-
Assets held on behalf of Neuroscience Consortium	872,177	1,891,305
Assets held in escrow	-	11,400,000
Prepaid expenses and other current assets	46,463	57,654
Assets committed under programs and awards:		
Cash and cash equivalents	31,082,771	26,486,076
Total current assets	<u>92,798,718</u>	<u>89,297,947</u>
Non-current assets:		
Loans receivable, net	4,928,250	4,470,750
Interest receivable, net	984,083	587,600
Net property and equipment	69,939	74,535
Total noncurrent assets	<u>5,982,272</u>	<u>5,132,885</u>
 Total assets	 <u>\$ 98,780,990</u>	 <u>\$ 94,430,832</u>
<b>LIABILITIES</b>		
Current liabilities:		
Accounts payable and accrued expenses	\$ 293,974	\$ 546,504
Grants payable and accrued grant expense	51,673,942	35,928,175
Total current liabilities	<u>51,967,916</u>	<u>36,474,679</u>
Noncurrent liabilities:		
Unearned revenue - Capital Program	-	11,400,000
Unearned revenue - Corporate Consortium	125,000	125,000
Agency obligation to the Neuroscience Consortium	872,177	1,891,305
Total liabilities	<u>997,177</u>	<u>13,416,305</u>
<b>NET POSITION</b>		
Net investment in capital assets	69,939	74,535
Unrestricted	45,745,958	44,465,313
Total net position	<u>45,815,897</u>	<u>44,539,848</u>
 Total liabilities and net position	 <u>\$ 98,780,990</u>	 <u>\$ 94,430,832</u>

The accompanying notes are an integral parts of these financial statements.

**Massachusetts Life Sciences Center**  
(A Component Unit of the Commonwealth of Massachusetts)  
Statements of Revenues, Expenses and Changes in Net Position  
Years Ended June 30, 2015 and 2014

	2015	2014
Operating income:		
Capital program revenues from Commonwealth of Massachusetts	\$ 77,645,075	\$ 49,314,049
Grant revenues	163,490	270,320
Sponsorship - Corporate Consortium	258,868	152,570
Interest income	467,486	410,701
Total operating income	<u>78,534,919</u>	<u>50,147,640</u>
Operating expenses:		
Grant expense	84,507,384	53,682,725
Salary and related employee expenses	2,229,767	1,960,143
Professional and consulting fees	439,108	291,116
Communications programs, sponsorships and contributions	293,867	313,406
General and administrative expenses	505,064	611,241
Loan loss reserve expense	732,420	2,179,750
Depreciation	31,148	31,912
Total operating expenses	<u>88,738,758</u>	<u>59,070,293</u>
Operating loss	<u>(10,203,839)</u>	<u>(8,922,653)</u>
Non-operating revenues:		
Investment income	90,119	67,574
Total nonoperating revenues	<u>90,119</u>	<u>67,574</u>
Loss before capital contributions	(10,113,720)	(8,855,079)
Contributions from the Commonwealth of Massachusetts	<u>11,389,769</u>	19,500,000
Increase in net position	1,276,049	10,644,921
Net position:		
Beginning of year	<u>44,539,848</u>	33,894,927
End of year	<u>\$ 45,815,897</u>	<u>\$ 44,539,848</u>

The accompanying notes are an integral parts of these financial statements.

**Massachusetts Life Sciences Center**  
(A Component Unit of the Commonwealth of Massachusetts)  
Statements of Cash Flows  
Years Ended June 30, 2015 and 2014

	2015	2014
Cash flows from operating activities:		
Receipts for reimbursements from the Commonwealth	\$ 63,517,472	\$ 44,720,202
Payments for grants	(68,871,061)	(48,873,201)
Payments for assets held in escrow	-	(11,400,000)
Receipts for unearned revenues - Capital Program	-	11,400,000
Payments for salary and related employee expenses	(2,246,480)	(1,916,723)
Payments for professional consulting fees	(564,608)	(243,959)
Payments for general and administrative expenses	(480,329)	(551,441)
Payments for communication programs, sponsorships and contributions	(419,688)	(228,477)
Receipts for grant revenues	184,023	61,341
Receipts for loan interest income	-	417,285
Receipts for sponsorships	258,868	277,570
Receipts for refunded grants	109,444	-
Net cash used in operating activities	<u>(8,512,359)</u>	<u>(6,337,403)</u>
Cash flows from capital and related financing activities:		
Receipt of contributions from the Commonwealth of Massachusetts	11,389,769	19,500,000
Net cash provided by capital and related financing activities	<u>11,389,769</u>	<u>19,500,000</u>
Cash flows from investing activities:		
Purchase of property and equipment	(26,550)	(73,532)
Issuance of loans	(1,500,000)	(3,984,500)
Repayment of loans	160,080	1,500,000
Receipt of investment income	90,119	67,574
Net cash used in investing activities	<u>(1,276,351)</u>	<u>(2,490,458)</u>
Net increase in cash and cash equivalents	1,601,059	10,672,139
Cash and cash equivalents:		
Beginning of year	43,343,450	32,671,311
End of year	<u>\$ 44,944,509</u>	<u>\$ 43,343,450</u>
Reconciliation of cash flows from operating activities:		
Operating loss	\$ (10,203,839)	\$ (8,922,653)
Adjustments to reconcile net operating loss to net cash used in operating activities:		
Depreciation expense	31,148	31,912
Loan loss reserve	732,420	2,179,750
Loan interest reserve	708,169	834,349
Changes in assets and liabilities:		
Accounts receivable	18,571	(208,414)
Grant reimbursement from Commonwealth	(14,127,603)	(4,593,847)
Interest receivable	(1,175,653)	(827,765)
Prepaid expenses and other current assets	11,191	(3,635)
Accounts payable and accrued expenses	(252,530)	259,454
Grants payable and accrued grant expense	15,745,767	4,809,524
Unearned revenues - Corporate Consortium	-	125,000
Unearned rent	-	(21,078)
Total adjustments	<u>1,691,480</u>	<u>2,585,250</u>
Net cash used in operating activities	<u>\$ (8,512,359)</u>	<u>\$ (6,337,403)</u>

The accompanying notes are an integral parts of these financial statements.

# Massachusetts Life Sciences Center

(A Component Unit of the Commonwealth of Massachusetts)  
Notes to Financial Statements  
Years Ended June 30, 2015 and 2014

---

## 1. ORGANIZATION

On June 24, 2006, the Commonwealth of Massachusetts (the "Commonwealth") enacted Section 24 of Chapter 123 of the Acts of 2006, creating the Massachusetts Life Sciences Center (the "Center") and establishing the Massachusetts Life Sciences Investment Fund (the "Investment Fund") to financially support its activities.

On June 16, 2008, the Life Sciences Act enacted by the Massachusetts Legislature was signed into law by Governor Deval Patrick. In that legislation, the Commonwealth committed to investing \$1 billion over a ten year period to create jobs, drive innovation and promote biomedical breakthroughs that improve people's lives. The Center is the steward and administrator of the \$1 billion and uses three statutory funding vehicles to achieve the Commonwealth's mission: the Life Sciences Investment Fund (the "Investment Fund"), the Capital Program and the Life Sciences Tax Incentive Program.

The Life Sciences Investment Fund is to be used in making appropriations, allocations, grants or loans to leverage development and investments in life sciences in Massachusetts. The Capital Program is for municipalities and institutions for buildings, equipment, upgrades to roads, sewer lines and other infrastructure that supports growth in the life sciences sector. The Life Sciences Tax Incentive Program allows the Center to award tax incentives on behalf of the Department of Revenue (DOR) to companies at every stage of development.

All grants and awards to be made by the Center require approval by its Board of Directors (the "Board of Directors").

The Center is governed by a seven member Board of Directors consisting of: the Secretary of Administration and Finance or her/his designee; the Secretary of Housing and Economic Development or his/her designee; the president of the University of Massachusetts or his/her designee; and four members appointed by the Governor, one of whom is a physician licensed to practice medicine in Massachusetts and affiliated with an academic medical center, one of whom is a CEO of a Massachusetts-based life sciences corporation that is a member of the board of directors of the Massachusetts Biotechnology Council, one of whom is a researcher involved in the commercialization of biotechnology, pharmaceuticals or medical diagnostic products and one of whom has significant financial experience in the life sciences sector.

In accordance with the requirements of Governmental Accounting Standards Board (GASB) Statement No. 14, *The Financial Reporting Entity*, GASB Statement No. 39, *Determining Whether Certain Organizations Are Component Units - an Amendment of GASB Statement 14*, and GASB Statement No. 61, *the Financial Reporting Entity: Omnibus - an amendment of GASB Statements No. 14 and No. 34*, the financial statements must present the Center and its component units. The Center has no component units. The Center, however, is considered a component unit of the Commonwealth and, accordingly, its financial statements are incorporated into the financial statements of the Commonwealth.

**Massachusetts Life Sciences Center**  
(A Component Unit of the Commonwealth of Massachusetts)  
Notes to Financial Statements  
Years Ended June 30, 2015 and 2014

---

**2. SIGNIFICANT ACCOUNTING PRINCIPLES**

Accounting and Reporting Standards

These financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP"), as prescribed by GASB codification section 2100, which establishes standards for defining and reporting on the financial reporting entity.

The GASB defines the basic financial statements of a business type activity as the: statement of net position, statement of revenues, expenses and changes in net position, and the statement of cash flows. The statement of net position is presented to illustrate both the current and noncurrent balances of each asset and liability. All revenues and expenses are classified as either operating or non-operating activities in the statement of revenues, expenses and changes in net position. Operating activities are those that support the mission and purpose of the Center. Nonoperating activities represent transactions that are capital, investing, legislative or regulated in nature.

The GASB requires that resources be classified into three categories of net position. Net position represents the residual interest in the Center's assets plus deferred outflows (as applicable) of resources after liabilities plus deferred inflows (as applicable) of resources are deducted and consist of: net investment in capital assets, restricted, and unrestricted, as follows:

Net Investment in Capital Assets

The net investment in capital assets component of net position consists of capital assets, net of accumulated depreciation, reduced by the outstanding balances of bonds, mortgages, notes, or other borrowings that are attributable to the acquisition, construction or improvement of those assets. Deferred outflows of resources and deferred inflows of resources that are attributable to the acquisition, construction, or improvement of those assets or related debt are included in this component of net position. For fiscal year 2015 and 2014 there were no deferred outflows or inflows of resources.

Restricted

Restricted net position represents the portion of net position subject to externally imposed stipulations that can be fulfilled by actions of the Center pursuant to those stipulations or that expire by the passage of time. At June 30, 2015 and 2014, the Center does not maintain any restricted net position.

Unrestricted

Unrestricted net position represents the portion of net position that is not subject to externally imposed stipulations. Unrestricted net position may be designated for specific purposes by action of management or the Board of Directors or may be otherwise limited by contractual agreements with outside parties. The Center's unrestricted net position includes appropriations received from the Commonwealth that are to be used for the general purposes of the Center. Per its enabling legislation, the Center may not expend more than fifteen percent of the amounts to be expended from the Life Sciences Investment Fund for the fiscal year for administrative expenditures and property and equipment.

**Massachusetts Life Sciences Center**  
(A Component Unit of the Commonwealth of Massachusetts)  
Notes to Financial Statements  
Years Ended June 30, 2015 and 2014

---

**2. SIGNIFICANT ACCOUNTING PRINCIPLES...continued**

Basis of Accounting

The financial statements were prepared using the accrual basis of accounting in conformity with accounting principles generally accepted in the United States of America ("GAAP"). Under the accrual basis, revenue is recognized when earned and expenses are recognized when obligations are incurred or when benefits are received.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents

Cash and cash equivalents consist of amounts on hand and highly liquid interest investments with maturities of three months or less from the date of acquisition.

Cash and Cash Equivalents or Reserved for Awards and Programs

Such amounts represent cash and cash equivalents to be expended for programmatic purposes based upon specific awards being made or programs authorized by the Board of Directors.

Assets Held in Escrow

Assets held in escrow relate to monies held in escrow by a third party in connection with the payment obligations of the Center under a grant agreement.

Revenue Recognition

Investment income is recognized as earned. Sponsorship revenues represent fees collected from companies for providing tradeshow booths and other space at industry trade shows. Sponsorship revenues are recognized when earned upon occurrence of the event. Consortium revenues are fees paid by corporations to sponsor and participate in the Center's small business matching grant and accelerator loan programs. Fees are for a specific time period and, accordingly, revenues are recognized over the specified time period.

Interest income is recognized as earned. Interest income on loans are reported net of any interest income loss reserve.

Capital program revenues are amounts due to the Center from the Commonwealth for related capital program expenditures by grantees of the Center. Capital program grantees submit requests for reimbursement to the Center after funds have been expended. The Center then bills the Commonwealth for these grantee expenses and recognizes the corresponding revenue.

Contributions from the Commonwealth are recognized when received from the Commonwealth.

**Massachusetts Life Sciences Center**  
 (A Component Unit of the Commonwealth of Massachusetts)  
 Notes to Financial Statements  
 Years Ended June 30, 2015 and 2014

**2. SIGNIFICANT ACCOUNTING PRINCIPLES...continued**

Loans Receivable and Interest Receivable, Net

Loans receivable, net, consists of loans issued by the Center to facilitate research, development, manufacturing and commercialization in life sciences by early stage companies. The loans have repayment terms of the earlier of 5 years or a qualified financing greater than \$5,000,000. The stated interest rate on each loan is 10% compounded annually.

As of June 30, 2015, \$22,691,196 of loans receivable has been authorized and \$18,691,500 has been disbursed. During fiscal year 2015, the Center funded \$1,500,000 in new loans and one borrower partially repaid their loan with a repayment of principal of \$160,000. As of June 30, 2014, \$18,691,500 of loans receivable had been authorized and \$17,191,500 had been disbursed. During fiscal year 2014, the Center funded \$3,984,500 million in new loans and two borrowers repaid their loans in full with a combined repayment of principal of \$1,500,000. Due to the nature of the loans made under this program, reserves are established at the time the loans are granted at a rate commensurate with management's estimate of historic loan loss. On a periodic basis, the Center assesses the collectability of each loan and records adjustments to those reserves based on an assessment of the financial condition of the borrower and loan performance. As of June 30, 2015, \$12,556,420 of loans receivable are outstanding and \$7,478,170 has been reserved for losses, resulting in net loans receivable of \$5,078,250. As of June 30, 2014, \$11,216,500 of loans receivable were outstanding and \$6,745,750 had been reserved for losses, resulting in net loans receivable of \$4,470,750. The Center had no write-offs or recoveries in fiscal year 2015 or 2014.

As of June 30, 2015, the gross interest receivable balance was \$3,377,584. As of June 30, 2014, the gross interest receivable balance was \$ 2,201,932. On a periodic basis, the Center assesses the collectability of the interest receivable and establishes a loss reserve in a manner consistent with loss reserves for loans receivable. As of June 30, 2015, \$2,322,502 has been reserved resulting in net interest receivable of \$1,055,082. As of June 30, 2014, \$1,614,332 had been reserved resulting in net interest receivable of \$587,600. Interest is due at the end of the loan term or upon repayment of the loan due to a qualified financing of these companies of greater than \$5,000,000.

Property and Equipment, Net

Property, equipment, and leasehold improvements with a value greater than \$500 are all stated at cost. Depreciation is recorded over the estimated useful lives of the assets by the straight line method. Expenditures for maintenance and repairs are charged to expense as incurred. Depreciation expense totaled \$31,148 and \$31,912 for the years ended June 30, 2015 and 2014, respectively. Estimated useful lives used for computing depreciation on property, equipment and leasehold improvements are as follows:

Computer equipment and software	3 years
Office equipment	3 years
Office furniture	3 years
Leasehold improvements	Shorter of the remaining term of lease or asset life

**Massachusetts Life Sciences Center**  
(A Component Unit of the Commonwealth of Massachusetts)  
Notes to Financial Statements  
Years Ended June 30, 2015 and 2014

---

**2. SIGNIFICANT ACCOUNTING PRINCIPLES...continued**

Grant Expense and Grants Payable

Grant expenses represent the current period cost of qualifying grant expenditures pursuant to the terms of each grant program. The Center had grant expense of \$84,507,384 and \$53,682,725 for fiscal year 2015 and 2014, respectively. As of June 30, 2015 and 2014, \$51,673,942 and \$35,928,175, respectively, was recorded as grants payable and accrued grant expense, representing grant expense incurred but not yet paid.

Income Taxes

Pursuant to Massachusetts General Laws chapter 231 §6(a), the operations of the Center constitute the performance of an essential government function and are therefore exempt from taxation by and within the Commonwealth.

Defined Contribution Plan

All employees of the Center participate in either the Commonwealth of Massachusetts State Retirement systems under a special funding situation where the Commonwealth of Massachusetts is a non-employer contributor under GASB Statement 68 or the statutorily prescribed optional defined contribution plan provided by the Center. The Center makes no contributions for employees participating in the Commonwealth of Massachusetts State Retirement systems' pension plan. In fiscal year 2010, as provided by the 2008 Statute, the Center established the optional defined contribution pension plan. The Center annually contributes an amount equal to 12% (5% statutorily mandated) of an employee's annual gross salary less the cost of life and disability insurance. Total optional defined contribution expense by the Center for the years ended June 30, 2015 and 2014 was \$167,967 and \$134,257, respectively. Vesting is immediate upon contribution. The Center pays administrative expenses of the Plan for the plan participants and ING is the custodian of the plan's assets. The balances of the plan are not included in the financial statements of the Center.

Related Party-Massachusetts Neuroscience Consortium

In June 2012, the Center announced the formation of a separate initiative, the Massachusetts Neuroscience Consortium (the "Consortium"), a collaboration between seven global pharmaceutical companies. The Consortium will fund pre-clinical neuroscience at Massachusetts academic and research institutions. Each Consortium member has agreed to contribute \$250,000 to the Consortium for the first year membership contribution. The Center is not a member of the Consortium and makes no financial contribution to the Consortium. The financial burden and administrative control does not reside with the Center. The designated members of the Consortium are responsible for all decisions regarding disbursement of funds. The Center acts solely as a custodian of the Consortium funds which are segregated in a separate bank account, the Center does not receive any fees for custodial services provided. In fiscal year 2015, the Consortium received \$500,000 plus interest from membership contributions to date held within the segregated bank account of the Center. In fiscal year 2014, the Consortium received \$1,000,000 plus interest from membership contributions plus interest from membership contributions to date held within the segregated bank account of the Center. The Consortium issued payments in the amount of \$1,522,008 during fiscal year 2015. The asset and corresponding liability balances of the Consortium are included in the financial statements of the Center as of June 30, 2015 and 2014. If the Consortium was to terminate, all remaining funds would be due back to the contributing members on a pro-rata basis.

**Massachusetts Life Sciences Center**  
(A Component Unit of the Commonwealth of Massachusetts)  
Notes to Financial Statements  
Years Ended June 30, 2015 and 2014

---

**2. SIGNIFICANT ACCOUNTING PRINCIPLES...continued**

Recent Accounting Pronouncements

In March 2012, the GASB issued GASB No. 65 – *Items Previously Reported as Assets and Liabilities*. GASB No. 65 provides clarification regarding the classification of deferred inflows and outflows of resources. The topics discussed in the standard are refunding of debt, nonexchange transactions, sales of future revenues, debt issuance costs, leases, acquisition of insurance costs, lending activities, mortgage banking, regulated activities, governmental fund revenue recognition and deferred revenue, major fund criteria and other items.

For the Center, the amendments in GASB No. 65 are effective beginning with the periods beginning after December 15, 2012. The adoption of this standard did not have a significant impact on the Center's financial statements.

In March 2012, the GASB issued GASB No. 66 – *Technical Correction – 2012 GASB No. 66* clarifies implementation issues that were presented in GASB No. 62 – *Codification of Accounting and Financial Reporting Guidance Contained in Pre-November 30, 1989 FASB and AICPA Pronouncements*. The standard provides clarification that the purchase price of loans is to include the amount paid to the seller plus any fees paid, less any fees, received. For the Center, the amendments in GASB No. 66 are effective beginning with the periods beginning after December 15, 2012. The adoption of this standard did not have a significant impact on the Center's financial statements.

In June 2012, the GASB issued GASB No. 67 – *Financial Reporting for Pension Plans*. GASB No. 67 replaces requirements of GASB Statements No. 25 and No. 50, related to pension plans administered through trusts or similar arrangements. The standard uses existing framework for financial reports of defined benefit pension plans, including a statement of fiduciary net position and a statement of changes in fiduciary net position. The standard enhances note disclosures and required supplementary information for both defined benefit and defined contribution pension plans. In addition, the standard requires the presentation of information about annual money-weighted rates of return in the notes and in 10-year required supplementary information schedules. For the Center, the amendments in GASB No. 67 are effective beginning with the fiscal year beginning after June 15, 2013. The adoption of this standard did not have a significant impact on the Center's financial statements.

In June 2012, the GASB issued GASB No. 68 – *Accounting and Financial Reporting for Pensions*. GASB No. 68 replaces requirements of GASB Statements No. 27 and No. 50, related to pension plans administered through trusts or similar arrangements. The standard requires governments providing defined benefit pensions to recognize their long-term obligation for pension benefits as a liability, and to more comprehensively and comparably measure the annual costs of pension benefits. In addition, the standard adds revised and new note disclosures and required supplementary information. For the Center, the amendments in GASB No. 68 are effective beginning with the fiscal year beginning after June 15, 2014. The adoption of this standard did not have a significant impact on the Center's financial statements.

**Massachusetts Life Sciences Center**  
(A Component Unit of the Commonwealth of Massachusetts)  
Notes to Financial Statements  
Years Ended June 30, 2015 and 2014

---

**2. SIGNIFICANT ACCOUNTING PRINCIPLES...continued**

Recent Accounting Pronouncements...continued

In January 2013, the GASB issued GASB No. 69 – *Government Combinations and Disposals of Government Obligations*. The standard establishes accounting and financial reporting standards related to government combinations and disposals of government operations. The term government combinations include a variety of transactions referred to as mergers, acquisitions, and transfers of operations. GASB No. 69 is effective for government combinations and disposals of government operations occurring in financial reporting periods beginning after December 15, 2013, and should be applied on a prospective basis. Earlier application is encouraged. The adoption of this standard did not have a significant impact on the Center's financial statements.

In April 2013, the GASB issued GASB No. 70 – *Accounting and Financial Reporting for Nonexchange Financial Guarantees*. The standard requires a government that extends a nonexchange financial guarantee to recognize a liability when qualitative factors and historical data, if any, indicate that it is more likely than not that the government will be required to make a payment on the guarantee. It requires a government that has issued an obligation guaranteed in a nonexchange transaction to report the obligation until legally released as an obligor. It also requires a government that is required to repay a guarantor for making a payment on a guaranteed obligation or legally assuming the guaranteed obligation to continue to recognize a liability until legally released as an obligor. The provisions of this standard are effective for reporting periods beginning after June 15, 2013. The adoption of this standard did not have a significant impact on the Center's financial statements.

In November 2013, the GASB issued GASB No. 71 – *Pension Transition for Contributions Made Subsequent to the Measurement Date (an amendment of GASB Statement No. 68)*. This Statement amends Statement 68 related to transition provisions for certain pension contributions made to defined benefit pension plans prior to implementation of Statement 68 by employers and nonemployer contributing entities. At the beginning of the period in which the provisions of Statement 68 are adopted, there may be circumstances in which it is not practical for a government to determine the amounts of all applicable deferred inflows of resources and deferred outflows of resources related to pensions. In such circumstances, the government should recognize a beginning deferred outflow of resources only for its pension contributions, if any, made subsequent to the measurement date of the beginning net pension liability but before the start of the government's fiscal year. Additionally, in those circumstances, no beginning balances for other deferred outflows of resources and deferred inflows of resources related to pensions should be recognized. The provisions of this Statement should be applied simultaneously with the provisions of Statement 68. The provisions of this standard are effective for reporting periods beginning after June 15, 2014. The adoption of this standard did not have a significant impact on the Center's financial statements.

In February 2015, GASB issued GASB Statement No. 72, *Fair Value Measurement and Application*, defines fair value and describes how fair value should be measured, what assets and liabilities should be measured at fair value, and what information about fair value should be disclosed in the notes to the financial statements.

**Massachusetts Life Sciences Center**  
(A Component Unit of the Commonwealth of Massachusetts)  
Notes to Financial Statements  
Years Ended June 30, 2015 and 2014

---

**2. SIGNIFICANT ACCOUNTING PRINCIPLES...continued**

Recent Accounting Pronouncements...continued

Under Statement No. 72, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Investments, which generally are measured at fair value, are defined as a security or other asset that governments hold primarily for the purpose of income or profit and the present service capacity of which are based solely on their ability to generate cash or to be sold to generate cash.

Before the issuance of Statement No. 72, state and local governments have been required to disclose how they arrived at their measures of fair value if not based on quoted market prices. Under the new guidance, those disclosures have been expanded to categorize fair values according to their relative reliability and to describe positions held in many alternative investments. The provisions of this standard are effective for reporting periods beginning after June 15, 2015. The implications on the fiscal practices and financial reports are being evaluated.

In June 2015, GASB issued GASB Statement No. 73, Accounting and Financial Reporting for Pensions and Related Assets That Are Not within the Scope of GASB Statement 68, and Amendments to Certain Provisions of GASB Statements 67 and 68, completes the suite of pension standards. Statement 73 establishes requirements for those pensions and pension plans that are not administered through a trust meeting specified criteria (in other words, those not covered by Statements 67 and 68). The requirements in Statement 73 for reporting pensions generally are the same as in Statement 68. However, the lack of a pension plan that is administered through a trust that meets specified criteria is reflected in the measurements. The provisions of this standard are effective for reporting periods beginning after June 15, 2015. The implications on the fiscal practices and financial reports are being evaluated.

In June 2015, GASB issued GASB Statement No. 74, Financial Reporting for Postemployment Benefit Plans Other Than Pension Plans, replaces GASB Statement No. 43, Financial Reporting for Postemployment Benefit Plans Other Than Pension Plans. Statement 74 addresses the financial reports of defined benefit OPEB plans that are administered through trusts that meet specified criteria. The Statement follows the framework for financial reporting of defined benefit OPEB plans in Statement 45 by requiring a statement of fiduciary net position and a statement of changes in fiduciary net position. The Statement requires more extensive note disclosures and RSI related to the measurement of the OPEB liabilities for which assets have been accumulated, including information about the annual money-weighted rates of return on plan investments. Statement 74 also sets forth note disclosure requirements for defined contribution OPEB plans. The provisions of this standard are effective for reporting periods beginning after June 15, 2016. The implications on the fiscal practices and financial reports are being evaluated.

In June 2015, GASB issued GASB Statement No. 75, Accounting and Financial Reporting for Postemployment Benefits Other Than Pensions, replaces the requirements of GASB Statement No. 45, Accounting and Financial Reporting by Employers for Postemployment Benefits Other Than Pensions. Among other things, Statement 75 requires governments to report a liability on the face of the financial statements for the OPEB that they provide and requires governments in all types of OPEB plans to present more extensive note disclosures and required supplementary information about their OPEB liabilities. The provisions of this standard are effective for reporting periods beginning after June 15, 2016. The implications on the fiscal practices and financial reports are being evaluated.

**Massachusetts Life Sciences Center**  
(A Component Unit of the Commonwealth of Massachusetts)  
Notes to Financial Statements  
Years Ended June 30, 2015 and 2014

---

**2. SIGNIFICANT ACCOUNTING PRINCIPLES...continued**

Recent Accounting Pronouncements...continued

In June 2015, GASB issued GASB Statement No. 76, The Hierarchy of Generally Accepted Accounting Principles for State and Local Governments, reduces the GAAP hierarchy to two categories of authoritative GAAP from the four categories under GASB Statement No. 55, The Hierarchy of Generally Accepted Accounting Principles for State and Local Governments. The first category of authoritative GAAP consists of GASB Statements of Governmental Accounting Standards. The second category comprises GASB Technical Bulletins and Implementation Guides, as well as guidance from the AICPA that is cleared by the GASB. The Statement also addresses the use of authoritative and nonauthoritative literature in the event that the accounting treatment for a transaction or other event is not specified within a source of authoritative GAAP. The provisions of this standard are effective for reporting periods beginning after June 15, 2015. The implications on the fiscal practices and financial reports are being evaluated.

In August 2015, GASB issued GASB Statement No. 77, Tax Abatement Disclosures, requires state and local governments, for the first time, to disclose information about tax abatement agreements. It requires governments to disclose information about their own tax abatements separately from information about tax abatements that are entered into by other governments and reduce the reporting government's tax revenues. The provisions of this standard are effective for reporting periods beginning after June 15, 2016. The implications on the fiscal practices and financial reports are being evaluated.

**3. RELATED PARTY TRANSACTIONS**

Certain of the Center's Board of Director's members have relationships with institutions that have received grants from the Center. Absent any statutory exemptions to the conflict of interest law, in circumstances where approval of such votes would create a conflict of interest, the Center's Board members are required to recuse themselves.

**4. CASH AND CASH EQUIVALENTS**

The Board of the Center is empowered under Chapter 231 of the MGL, which shall have all powers necessary or convenient to carry out and effectuate its purposes, including, without limiting the generality of the foregoing, the powers: to invest any funds held in reserves or sinking funds, or the Massachusetts Life Sciences Investment Fund, or any funds not required for immediate disbursement, in such investments as may be provided in any financing document relating to the use of such funds, or, if not so provided, as the Board of Directors may determine. During fiscal year 2015 and 2014, these assets were majority allocated to short-term investments/money market accounts which qualify as cash equivalents and are carried at amortized cost.

**Massachusetts Life Sciences Center**  
(A Component Unit of the Commonwealth of Massachusetts)  
Notes to Financial Statements  
Years Ended June 30, 2015 and 2014

**4. CASH AND CASH EQUIVALENTS...continued**

Custodial Credit Risk – Deposits

Custodial credit risk for deposits exists when, in the event of failure of a depository financial institution, the Center's deposits may not be recovered. The Center does not have a policy for custodial risk. At June 30, 2015, bank deposits were \$10,151,738 which excludes the amount held in the Massachusetts Municipal Depository Trust ("MMDT" or the "Trust"). The Center invests some of its funds in the MMDT, an investment pool for political subdivisions of the Commonwealth designed as a legal means to invest temporarily available cash. The state treasurer serves as trustee of MMDT, and has sole authority pertaining to rules, regulations and operations of the Trust. A participant's holdings in the Trust are not subject to creditors of the Commonwealth, nor will the Trust itself be affected by the financial difficulties of any participant. Amounts held at MMDT are uninsured and uncollateralized. At June 30, 2015 The Center's deposits with MMDT totaled \$34,792,771. A copy of the financial statements of MMDT can be obtained from the Office of the State Treasurer, 1 Ashburton Place, Boston, MA 02110.

The following summarizes the cash and cash equivalents of the Center and identifies certain types of investment risk as defined by GASB Statement No. 40, *Deposit and Investment Risk Disclosures*, at June 30:

	<u>2015</u>	<u>2014</u>
Cash deposits	\$ 10,151,738	\$ 6,624,942
Massachusetts Municipal Depository Trust ("MMDT") Cash Portfolio	<u>34,792,771</u>	<u>36,718,508</u>
	<u>\$ 44,944,509</u>	<u>\$ 43,343,450</u>

**5. PROPERTY AND EQUIPMENT, NET**

Property and equipment, net, at June 30 consisted of the following:

	<u>2015</u>	<u>2014</u>
Computer equipment	\$ 126,934	\$ 119,400
Office furniture	178,819	178,819
Leasehold improvements	<u>103,157</u>	<u>100,596</u>
	408,910	398,815
Accumulated depreciation	<u>(338,971)</u>	<u>(324,280)</u>
Property and equipment, net	<u>\$ 69,939</u>	<u>\$ 74,535</u>

**6. ACCOUNTS PAYABLE AND ACCRUED EXPENSES**

As of June 30, 2015 and 2014, accounts payable and accrued expenses totaled \$293,974 and \$546,504, respectively. Those expenses primarily accounted for accrued salary, professional and consulting fees and marketing expenses.

**Massachusetts Life Sciences Center**  
(A Component Unit of the Commonwealth of Massachusetts)  
Notes to Financial Statements  
Years Ended June 30, 2015 and 2014

---

**7. GRANTS AND COMMITMENTS**

Investment Fund

The following grants were made out of the Massachusetts Life Sciences Investment Fund (the "Investment Fund"):

In October 2007, the Board of Directors voted to approve two grants for the University of Massachusetts Medical School: 1) \$570,000 for funding for a stem cell registry; and 2) \$7,665,000 for a stem cell bank. In June 2009, the Board of Directors voted to approve an additional \$695,000 for the stem cell registry. In September 2010, the Board of Directors voted to approve an additional \$440,000 for the stem cell registry. In January and May 2012, the Board of Directors voted to approve an additional \$950,000 for the stem cell bank. In May 2013, the Board of Directors voted to approve an additional \$270,000 for the stem cell registry. For the year ended June 30, 2015, the Center incurred no expense under the grants. For the year ended June 30, 2014, the Center expensed \$193,516. As of June 30, 2015, there are no remaining commitments under the program.

In July 2008, the Board of Directors voted to approve \$6,918,378 in funding for two research matching grant programs to attract top scientific talent, spur new research opportunities and increase industry-sponsored research. Specifically, the Board of Directors awarded five new faculty grants totaling \$3,750,000 to various Massachusetts universities. The Board of Directors also awarded eleven new investigator grants totaling \$3,168,378 to a variety of research centers. For the year ended June 30, 2015, the Center expensed \$77,508 of which \$77,508 is not paid and is included in grants payable and accrued grant expense on the statement of net position. The Center also reversed \$16,294 of expense due to actual expense less than an estimate provided by an awardee from a previous fiscal year. For the year ended June 30, 2014, the Center reversed \$22,718 of expense due to actual expense less than an estimate provided by an awardee from the previous fiscal year.

In December 2008, the Board of Directors voted to approve \$3,786,867 for six cooperative research grants over a three-year period to foster collaborations between scientists, academic institutions and industry. In fiscal year 2012, one of the awards was mutually terminated due to a change in focus by the industry sponsor. As of June 30, 2015, there are no remaining commitments under the program.

In April 2011, the Board of Directors voted to approve \$1,000,000 for two cooperative research grants. For the year ended June 30, 2015, the Center expensed and paid \$257,548. For the year ended June 30, 2014, the Center expensed \$311,262. As of June 30, 2015, there are no remaining commitments under the program.

In June 2013, the Board of Directors voted to approve \$2,000,000 for four cooperative research grants. For the year ended June 30, 2015, the Center expensed \$1,091,439, of which \$425,731 was not paid as of June 30, 2015 and is included in grants payable and accrued grant expense on the statement of net position. For the year ended June 30, 2014, the Center expensed \$650,812. Remaining commitments under the authorized grants are \$683,481 as of June 30, 2015.

In June 2015, the Board of Directors voted to approve \$1,990,380 for six cooperative research grants. For the year ended June 30, 2015, the Center expensed no dollars. Remaining commitments under the authorized grants are \$1,990,380 as of June 30, 2015.

**Massachusetts Life Sciences Center**  
(A Component Unit of the Commonwealth of Massachusetts)  
Notes to Financial Statements  
Years Ended June 30, 2015 and 2014

---

**7. GRANTS AND COMMITMENTS...continued**

Investment Fund...continued

In December 2014, the Board of Directors authorized \$3,000,000 for the 2015 Internship Challenge Program which is a year round program. For the year ended June 30, 2015, the Center expensed \$765,320 for the program, of which \$752,454 was not paid as of June 30, 2015 and is included in grants payable and accrued grant expense on the statement of net position. In December 2013, the Board of Directors authorized \$3,000,000 for the 2014 Internship Challenge Program. For the year ended June 30, 2015, the Center expensed \$1,882,834 for the program, and \$303,037 is included in grants payable and accrued grant expense on the statement of net position. For the year ended June 30, 2014, the Center expensed \$723,926. In December 2012, the Board of Directors authorized \$3,200,000 for the 2013 Internship Challenge Program. For the 2013 program, the Center reversed \$75,580 of expense in fiscal year 2015 due to an over accrual in fiscal year 2014. For the year ended June 30, 2014, the Center expensed \$1,751,828.

In December 2011, the Board of Directors authorized \$3,200,000 for the 2012 Internship Challenge Program. For the 2012 program, the Center reversed \$14,400 of expense in fiscal year 2014 due to an over accrual in fiscal year 2013. Remaining payments under all authorized Internship Challenge Programs are \$3,683,412.

In May 2015, the Board of Directors voted to approve 12 awards totaling \$2,242,335 in grant funding for the Milestone Achievement Program ("MAP") to enable early stage companies in achieving critical, value creating milestones. For the year ended June 30, 2015, the Center expensed \$1,054,520. Remaining commitments under the grants are \$1,687,816 as of June 30, 2015.

Other Grants

The Center has made grants to various business plan competitions, workforce development and educational programs to foster company development and collaboration between Massachusetts and international organizations and expand life sciences education and workforce within the Commonwealth. For the fiscal years ended June 30, 2015 and June 30, 2014 the Center had \$1,005,844 and \$1,048,228 of active discretionary grants, respectively. In fiscal year 2015 the Center expensed \$453,648 of which \$221,257 was unpaid as of June 30, 2015 and is included in grants payable and accrued grant expense on the statement of net position as of June 30, 2015. In fiscal year 2014 the Center expensed \$501,342. Remaining commitments under the authorized grants are \$391,155 as of June 30, 2015.

**Massachusetts Life Sciences Center**  
(A Component Unit of the Commonwealth of Massachusetts)  
Notes to Financial Statements  
Years Ended June 30, 2015 and 2014

---

**7. GRANTS AND COMMITMENTS...continued**

Other Grants...continued

In May of 2012, the Center made one award of \$300,000 to the Massachusetts Eye and Ear Infirmary under the Northern Ireland Massachusetts Connection Program, which has a goal of creating biotech research and business collaborations between Massachusetts, Northern Ireland and Europe. In fiscal year 2012, the Board of Directors authorized two awards for \$300,000 under the Massachusetts Israeli Innovation Partnership Program to foster international collaboration on early-stage life sciences projects. One of the awards will not be funded due to the awardee's inability to comply with requirements of the program. In fiscal year 2013, the Board of Directors authorized two awards totaling \$450,170 under the second round of the Massachusetts Israeli Innovation Partnership Program. In February of 2014, the Board of Directors authorized four awards for \$1,059,750 under the International Collaborative Industry Program. In February 2015, the Board of Directors authorized four awards for \$1,600,000 under the second round of the International Collaborative Industry Program. During fiscal year 2015, the Board of Directors authorized seven awards totaling \$1,363,400 under the Universal Partnership Program which provides grants to Massachusetts companies to support collaboration on R&D with a non-U.S. organization. In September 2014, the Board of Directors authorized \$550,000 to Center for the Advancement of Science in Space ("CASIS") for administering a program to permit Massachusetts companies and schools to perform scientific experiments on the International Space Station. In December 2014, the Board of Directors authorized an award of \$1,000,000 to Diagnostics for All focusing on developing rapid Ebola diagnostic testing kits. The Center expensed \$1,371,366 related to the above programs, of which \$911,492 was unpaid and is included in grants payable and accrued grant expense on the statement of net position as of June 30, 2015. For the year ended June 30, 2014 the Center expensed \$302,227. Remaining commitments under the authorized grants are \$5,088,384 as of June 30, 2015.

In fiscal year 2012, the Center made an additional \$50,000 grant to the Massachusetts Life Sciences Collaborative to launch and develop a formal Massachusetts Biomanufacturing Roundtable to support and promote the retention and growth of biomanufacturing in Massachusetts. The total amount of awards provided to the Massachusetts Biomanufacturing Roundtable is \$100,000. In fiscal year 2014 the Center expensed \$10,719 of which all was paid as of June 30, 2014. As of June 30, 2015, there are no remaining commitments under the program.

Total remaining commitments for all Investment Fund grants as of June 30, 2015 are \$14,064,435.

**Massachusetts Life Sciences Center**  
 (A Component Unit of the Commonwealth of Massachusetts)  
 Notes to Financial Statements  
 Years Ended June 30, 2015 and 2014

**7. GRANTS AND COMMITMENTS...continued**

Capital Program Grants

The following table summarizes active grants in fiscal year 2014 and/or 2015 under the Capital Program:

Awardee	Location	Award Amount	Expensed FY15	Expensed FY14	Expensed Prior to FY14	Amount in Grants Payable Accrued Grant Expense as of June 30, 2015	Remaining payments as of June 30, 2015
Bay Path University	Longmeadow	\$ 500,000	\$ -	\$ -	\$ -	\$ -	\$ 500,000
Baystate Medical	Springfield	5,500,000	2,863,264	2,178,804	-	1,370,776	1,828,708
Berkshire Community College	Pittsfield	500,000	-	-	-	-	500,000
Boston Children's Hospital	Boston	2,263,133	-	-	-	-	2,263,133
Brigham & Women's Hospital/Forsyth Institute	Boston	4,813,766	-	-	-	-	4,813,766
BU Medical School	Boston	1,743,648	-	-	-	-	1,743,648
BU: Biomedical Lab and Clinical Sciences Program	Boston	180,000	-	-	-	-	180,000
BU: Business Innovation Center	Boston	363,750	-	-	-	-	363,750
Children's Hospital	Boston	4,014,031	510,233	2,814,325	689,473	-	-
City of Pittsfield	Pittsfield	9,725,000	460,761	55,000	-	267,808	9,477,047
City of Taunton	Taunton	55,000	32,450	-	-	32,450	55,000
Dana-Farber Cancer Institute	Boston	10,000,000	-	7,545,546	2,454,454	-	-
Framingham State University	Framingham	3,000,000	3,000,000	-	-	3,000,000	3,000,000
FY14 College Planning/Equip	Various	811,135	83,336	727,799	-	88,336	68,336
FY15 College Planning/Equip	Various	2,491,464	1,753,252	-	-	999,203	1,737,415
Harvard Medical School	Cambridge	5,000,000	1,049,921	3,037,025	212,975	135,028	835,107
Holyoke Community College	Holyoke	3,800,000	3,000,000	-	-	-	800,000
Holyoke Community College	Holyoke	300,000	-	-	-	-	300,000
Just-A-Start Corporation	Cambridge	49,992	-	-	-	-	49,992
Lab Central	Cambridge	5,000,000	-	-	-	-	5,000,000
LabCentral	Cambridge	4,955,515	-	4,139,375	816,140	-	-
North Shore Biotech Consortium	See Note	5,000,000	4,243,131	-	-	3,206,038	3,962,907
M.I.T.	Cambridge	1,838,000	83,041	-	-	83,041	1,838,000
MA Green High Performing Computing Center	Holyoke	4,540,000	1,553,116	1,863,961	-	1,491,042	2,613,965
Univ. of Mass/ Medical School - MassBiologics	Boston	5,000,000	3,189,961	-	-	3,189,961	5,000,000
Middlesex Community College	Bedford/Lowell	3,000,000	-	-	-	-	3,000,000
New Bedford Economic Development Council	New Bedford	75,000	55,000	20,000	-	-	-
Northern Essex Community College	Haverhill/Lawrence	1,242,000	816,830	401,134	9,747	158,352	172,651
Quinsigamond Community College	Worcester	5,000,000	-	-	-	-	5,000,000
Regis College	Weston	355,000	-	-	-	-	355,000
Roxbury Community College	Roxbury Crossing	3,000,000	-	-	-	-	3,000,000
Springfield Technical Community College	Springfield	1,000,000	-	-	-	-	1,000,000
The Forsyth Institute	Boston	4,133,215	923,264	2,206,805	1,003,146	594,218	594,218
Univ. of Mass/ Amherst	Amherst	95,000,000	28,767,103	11,619,681	308,000	22,367,579	76,672,795
Univ. of Mass/ Boston Venture Development Center	Boston	588,848	310,155	-	-	-	278,693
Univ. of Mass/ Boston-DF/HCC	Boston	10,000,000	842,903	1,595,834	232,910	842,903	8,171,256
Univ. of Mass/ Dartmouth - ATMC	Fall River	11,400,000	11,400,000	-	-	-	-
Univ. of Mass/ Dartmouth - MAB	Fall River	20,600,000	-	5,815,537	14,784,463	-	-
Univ. of Mass/ Lowell - ETIC	Lowell	10,000,000	2,018,642	3,431,448	4,549,910	2,018,642	2,018,642
Univ. of Mass/ Lowell - Innovation Hub	Lowell	5,046,697	4,251,573	-	-	4,251,573	5,046,697
Univ. of Mass/ Medical School	Boston	5,000,000	3,484,300	-	-	3,484,300	5,000,000
Venture Café	Boston	347,000	62,325	145,144	-	1,008	140,539
Wellesley College	Wellesley	50,000	-	-	-	-	50,000
Worcester Polytechnic Institute	Worcester	5,149,999	-	114,300	5,035,699	-	-
		\$ 262,432,193	\$ 74,754,561	\$ 47,711,718	\$ 30,096,917	\$ 47,562,268	\$ 157,431,265

Note: The North Shore Biotech Consortium is comprised of the following organizations: Endicott College, Gordon College, Salem State University, North Shore Community College and North Shore Innoventures.

STEM Equipment and Supplies

Year	Location						
FY13 Program	Various	\$ 3,212,860	\$ -	\$ 1,602,333	\$ 1,610,527	\$ -	\$ -
FY14 Program	Various	3,272,862	2,999,956	-	-	920,194	1,193,100
FY15 Program	Various	3,774,535	-	-	-	-	3,774,535
		\$ 10,260,257	\$ 2,999,956	\$ 1,602,333	\$ 1,610,527	\$ 920,194	\$ 4,967,635

**Massachusetts Life Sciences Center**  
 (A Component Unit of the Commonwealth of Massachusetts)  
 Notes to Financial Statements  
 Years Ended June 30, 2015 and 2014

**7. GRANTS AND COMMITMENTS...continued**

Other Capital Programs

In May 2012, the Center's Board of Directors awarded \$500,000 in a Small Business Matching grant to one life sciences company in Massachusetts. To qualify for the program, companies must have received a Phase II or Post Phase II small business innovation research ("SBIR") or small business technology transfer ("STTR") grant from federal agencies such as the National Institutes of Health ("NIH"), National Science Foundation ("NSF"), or Department of Defense ("DOD"). The Center did not offer the program in fiscal year 2013. For the year ended June 30, 2015, the Center did not incur any expense under the program. The Center did recover \$109,444 from a prior awardee under the program in fiscal year 2015. There no remaining commitments under the program as of June 30, 2015.

Total remaining commitments for all capital program grants as of June 30, 2015 are \$162,398,900 which is contingent upon the Commonwealth fulfilling their funding obligations to the Center.

Facility Lease

In December 2008, the Center entered into a 5 year noncancelable operating lease through March 2014 for its facilities in Waltham, Massachusetts. In June 2013, the Center renewed its lease with expansion space to be occupied in October 2013. The renewed lease is through March 2019. Rent expense under the operating lease was \$263,175 for the year ended June 30, 2015 and \$216,051 for the year ended June 30, 2014.

Future minimum lease payments under all operating lease agreements are approximately:

2016	\$	263,000
2017		263,000
2018		263,000
2019		<u>197,000</u>
	\$	<u>986,000</u>

**8. SUBSEQUENT EVENTS**

Management has evaluated subsequent events through September 25, 2015.

In August 2015, the Center disbursed \$1,000,000 to a May 2015 Accelerator loan program awardee.

**Independent Auditors Report on Internal Control Over Financial Reporting and  
on Compliance and Other Matters Based on an Audit of Financial Statements  
Performed in Accordance With Government Auditing Standards**

To the Board of Directors of the  
Massachusetts Life Sciences Center  
Waltham, Massachusetts

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the financial statements of the Massachusetts Life Sciences Center (the "Center"), a component unit of the Commonwealth of Massachusetts as of and for the year ended June 30, 2015, and the related notes to the financial statements, which collectively comprise Center's basic financial statements, and have issued our report thereon dated September 25, 2015.

**Internal Control over Financial Reporting**

In planning and performing our audit of the financial statements, we considered Center's internal control over financial reporting (internal control) to determine the audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of Center's internal control. Accordingly, we do not express an opinion on the effectiveness of Center's internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

**Compliance and Other Matters**

As part of obtaining reasonable assurance about whether the Center's financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the determination of financial statement amounts. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

**Purpose of this Report**

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Boston, Massachusetts  
September 25, 2015

Preliminary and Tentative For Discussion Purposes Only